CN100345592C - Mono and disaccharide derivatives - Google Patents

Abstract

The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for medical, pharmaceutical, cosmetic and food applications.

Description

Monosaccharide and two sugar derivativess

The present invention relates to the family of new monosaccharide derivatives and two sugar derivativess and relate to its preparation method.The invention further relates to the use of said derivant in medical science, pharmacy, cosmetics and food applications.

Sugar fatty acid ester is with its emulsifying capacity widely.They can carry out emulsifying to big decentralized photo with the continuous phase of little oil immersion water or water logging oil type.In addition, sugar fatty acid ester with its widely HLB value (hydrophilic-lipophile balance, the HLB value of sucrose fat can change between＜1 to 16) known by the people.The HLB value of sugar fatty acid ester is decided according to the length of the fatty ester number of each glycan molecule and this fatty acid ester carbochain.

Sugar fatty acid ester is further known with several other application, and for example their strengthen or suppress fat and oily crystalline ability, their antibacterial effect, their infiltration and dispersion effect, their possible purposes and reinforced effects of their non-specific host defenses in protein thermal denaturation and cold denaturation inhibitory action.

People such as Nigam (Da Ying cancer magazine, 1982,46,782-793 page or leaf) disclose in various arabinose, galactose, glucose, mannose, cellobiose, lactose, maltose and the sucrose fatty acid ester born of the same parents and the outer immunostimulating effect of born of the same parents.The growth indices of antibody response changes between 1 to＜10.

People such as Nigam (cancer research, 1978,38,3315-3312 page or leaf) disclose two sugar fatty acid esters, especially maltose tetrapalmitate, immune-enhancing activity.

People such as Nishikawa (chemical drugs bulletin, 1981,29,505-513 page or leaf) disclose the anti-tumor activity of sucrose fatty acid ester.

Azuma (EP 1,572,368) discloses the reinforced effects of sugar fatty acid ester aspect vaccine effect power (being called " adjuvanticity " or " adjuvanticity " herein).

Two sugar fatty acid esters that combine with emulsion oil-in-water with it to the effect of stimulation of vaccine effect power and known.

People such as Nigam (Da Ying cancer magazine, 1982,46,782-793 page or leaf) also disclose the compositions of emulsion oil-in-water of a kind of sucrose fatty acid ester and Squalene and they purposes as adjuvant.Yet verified, sucrose octaoleate ester also is very faint (referring to the following examples) to the effect of stimulation of vaccine effect power if any.Even the compositions of the emulsion oil-in-water of sucrose octaoleate ester and Squalene also only has faint reinforced effects to vaccine effect power, this makes it and is not suitable as vaccine adjuvant and uses (referring to the following examples).

The sucrose sulfuric ester is also known by the people.United States Patent (USP) 3,432,489 disclose the method for a kind of synthetic various disaccharide poly sulfuric esters and its aluminum complex, and relevant therapeutic equipments.This patent has more specifically described sucrose and multiple sulfur acidizing reagent (is included in chlorosulfonic acid or SO in all ingredients (comprising pyridine) ₃-pyridine) reaction.In addition, United States Patent (USP) 3,432,489 disclose the sucrose sulfuric ester, the complex of sucrose octaoleate ester and aluminum salt (also being known as sucralfate) especially, pharmacy and medical usage.Sucralfate is also known by the people in the application aspect the treatment gastro intestinal disorders.

W/O 90/02133 disclose a kind of method for preparing sucrose sulfuric ester and aluminum complex thereof with and the prescription of medical usage.

People such as Bazin (carbohydrate compound research, 1998,309,189-205 page or leaf) disclose by the regional method of selecting to synthesize based on the surfactant of sucrose of the sulphofication of acyl sucrose.Its each sucrose molecule of disclosed derivant comprises a carboxyl groups and a sulfonic acid group.Its disclosed method is the regional selection method of some hydroxyl that sucrose molecule is derived.This method uses dibutyl stannylene complex to seal some hydroxyl.A shortcoming of this method is that it is too complicated.

People such as Hilgers (immunology, 1986,60,141-146 page or leaf) disclose the polysaccharide (being also referred to as sulfonate grease-polysaccharide) of fatty acid esters and sulfuric ester, and they in vaccine as the purposes of adjuvant.In addition, people such as Hilgers (immunology, 1986,60,141-146 page or leaf; WO 96/20222) disclose and a kind ofly prepared the method for sulfonate grease-polysaccharide by polysaccharide being contacted with acyl chlorides (acoylchloride) and then contacting with sulfonating agent.

Mashihi and Hilgers (EP-A-0-295,749) disclose compositions, especially the hydrophilic sulfonate grease-polysaccharide of a kind of sulfonate grease-polysaccharide and O/w emulsion and the compositions of water bag squalane (squalane) emulsion.Mashihi and Hilgers (EP-A-0-295,749) also disclose compositions on non-specific host epidemic preventing mechanism the reinforced effects of sulfonate grease-polysaccharide (especially hydrophilic sulfonate grease-polysaccharide) with O/w emulsion (especially water bag squalane emulsion).

People such as Hilgers (vaccine, 1994,12,653-660 page or leaf; Vaccine, 1994,12, the 661-665 page or leaf; WO 96/20008; Vaccine, 1999,17,219-228 page or leaf) compositions of sulfonate grease-polysaccharide (especially hydrophilic sulfonate grease-polysaccharide) with O/w emulsion (especially water bag squalane emulsion, water bag mineral oil emulsion, water bag soybean oil emulsion and water bag hexadecane) disclosed.The method for preparing sulfonate grease-polysaccharide (especially hydrophilic sulfonate grease-polysaccharide) and O/w emulsion (especially water bag squalane emulsion, water bag mineral oil emulsion, water bag soybean oil emulsion and water bag hexadecane) composition stable preparation is also disclosed.

The method of preparation disclosed sulfonate grease-polysaccharide in WO 96/20008 comprised for two steps; (1) at first, this polysaccharide is contacted with acyl chlorides, (2) contact greasy polysaccharide derivates with sulfonating agent then.Two steps all were considered to chemical additive reaction at random, and the esterified probability of each hydroxyl equates on the polysaccharide molecule in other words, and can not change in processing procedure.This method for preparing sulfonate grease-polysaccharide has produced the prescription of different sulfonate grease-polysaccharide derivates, and its variation is the number and the distribution in polysaccharide molecule of fatty acid ester, sulfuric ester and hydroxyl of hydroxyl in the number of sulfuric ester in the number of fatty acid ester in every polysaccharide molecule, the every polysaccharide molecule, the every polysaccharide molecule.The number by different polysaccharide molecules in the parent material and the hydroxy number of each polysaccharide molecule can be determined the number that different sulfonate grease-polysaccharide derivates is chemically arranged that obtains in preparation.

For in sulfonate grease-polysaccharide prepared product, existing many chemically different sulfonate grease-polysaccharide derivates to carry out illustration, special the disclosed embodiment of people such as Hilgers (WO 96/20008) is described below.

The most clearly sulfonate grease-polysaccharide as known in the art, the chemically defined sulfonate grease-polysaccharide prepared product (be also referred to as sulfonate grease-cyclodextrin) of prepared product of deriving for obtaining by beta-schardinger dextrin-.This sulfonate grease-cyclodextrin prepared product has the polysaccharide of 7 glucose molecules to obtain by each polysaccharide molecule.This sulfonate grease-cyclodextrin prepared product is from the polysaccharide of lowest molecular weight, and has disclosed minimum hydroxyl value.The molecular weight of beta-schardinger dextrin-is that 1153Da and each molecule have 21 hydroxyls.These hydroxyls can carry out chemical addition by fatty acid ester or sulfuric ester, perhaps can remain unchanged.Being present in derivant in sulfonate grease-cyclodextrin prepared product mixes at the hydroxy number of the sulfuric ester number of the fatty acid ester number of each beta-schardinger dextrin-molecule, each beta-schardinger dextrin-molecule, each beta-schardinger dextrin-molecule and these fatty acid esters, sulfuric ester and the hydroxyl branch on the beta-schardinger dextrin-molecule and has nothing in common with each other.According to methods known in the art (vaccine, 1999,17,219-22 page or leaf; WO 96/20222) the number of chemically different derivants in the sulfonate grease-cyclodextrin prepared product of preparation is very high.If not with fatty acid ester, sulfuric ester and the hydroxyl Distribution Calculation on the beta-schardinger dextrin-molecule interior, the number of chemically different derivants can have hundreds of (for example 210) in sulfonate grease-cyclodextrin prepared product.In addition, if with fatty acid ester, sulfuric ester and the hydroxyl Distribution Calculation on the beta-schardinger dextrin-molecule interior, the number of chemically different derivants is 3 in sulfonate grease-cyclodextrin prepared product ³+ { (3 ³) ⁷-3 ³}/7=1,494,336,195.

Disclosed as people such as Hilgers (WO 96/20008), the concentration that is present in this chemically different derivant in sulfonate grease-cyclodextrin prepared product can be by changing parent material, and promptly the molar ratio of beta-schardinger dextrin-, acyl chlorides and sulfonating agent or part by weight are adjusted.The concentration that is present in this chemically different derivant in sulfonate grease-cyclodextrin prepared product can be carried out mathematical estimation.If two kinds of chemical reactions of this that relates in sulfonate grease-cyclodextrin prepared product are completely randoms, are present in the maximum concentration of a certain derivant in sulfonate grease-cyclodextrin prepared product so and all can be less than 5% most of the time.Sulfonate grease-polysaccharide the prepared product that obtains by the polysaccharide more than the hydroxyl value beta-schardinger dextrin-of per molecule polysaccharide can contain greater number chemically different derivants and corresponding the concentration of every kind of derivant lower.

Therefore, can reach a conclusion, (WO 96/20002 as people such as Hilgers; WO96/20008) disclosed such sulfonate grease that obtains-polysaccharide prepared product contains many chemically different derivants, and it may be disadvantageous under certain environment.And very low this fact of the amount of specific derivatives may be disadvantageous.

The shortcoming of this sulfonate grease-polysaccharide is that they have various physics, chemistry and physicochemical properties (as dissolubility, surface activity), when they are suitable for carrying out certain use (for example detergent or emulsifying agent), they but are not suitable for using and/or be unsuitable for other purposes with other molecule.For this reason, need the sulfonate grease-polysaccharide derivates of " unaccommodated " sulfonate grease-polysaccharide derivates with " being fit to " separated.Such separation process can be undertaken by the isolation technics of the classics known in this area.Yet such as mentioned, the concentration that " is fit to " derivant in sulfonate grease-polysaccharide prepared product is relatively low.And the chemistry and the physical property of sulfonate grease-polysaccharide derivates of chemistry of " unaccommodated " sulfonate grease-polysaccharide derivates and physical property and " being fit to " may be closely similar.Therefore, this separation method may be very complicated, expensive and time-consuming.

(WO 96/20002 for people such as Hilgers; WO 96/20008) another shortcoming of disclosed sulfonate grease-polysaccharide prepared product is that it has used a large amount of comparatively speaking organic solvents, and these solvents need be removed from final sulfonate grease-polysaccharide prepared product.This also be usually difficulty also/or relate to the use of some difficulties, costliness or even danger (especially for commercial scale) method.

Therefore, the sugar derivatives that is extensive use of, has physical chemistry and/or biology and/or biological medicine character that can satisfy various purposes is still had tangible demand.And to easily, the method for the such sugar derivatives of preparation also has demand on the cheap again commercial scale of safety.

Purpose of the present invention just provides the sugar derivatives that can form stabilization formulations with various water-fast molecules.The purpose sugar derivatives should have high advantage physics and/or physical chemistry and/or biology and/or pharmaceutical properties, uses thereby they are accommodated in various application (for example medical application is as in the preparation of vaccine and/or vaccine adjuvant).Another object of the present invention provide a kind of simple, be easy to and the method for the sugar derivatives that cheap preparation is such.

The invention provides sugar derivatives with high advantage chemistry, physics and physicochemical properties.These derivants are monosaccharide and two glycan molecules to be carried out various chemistry (and/or zymetology) modify resulting.

The present invention relates to sugar derivatives, wherein at least one free hydroxyl group (preferably having 8 free hydroxyl groups on two glycan molecules) of at least one free hydroxyl group of monosaccharide molecule (3,4 or 5 free hydroxyl groups are arranged on the monosaccharide molecule) or two glycan molecules is modified.These modifications be with various substituted radicals to or hydroxyl on hydrogen atom or the replacement carried out of whole oh group itself.In this way, different according to quantity that replaces and type, the monosaccharide or two sugar derivativess that can obtain to have required character.

Specifically, the present invention relates to a kind of new, have 1 monosaccharide or two sugar derivativess to N-1 fatty acid ester group, wherein N refers to obtain the monosaccharide of derivant or the hydroxyl value of disaccharide.In a preferred embodiment, monosaccharide or two sugar derivativess also contain 1 to N-1 anionic group and wherein the combined number of fatty acid ester group and anionic group be no more than N.The combined number of anionic group and fatty acid ester group is between 1 to N.Preferably, no more than two of the free hydroxyl group of monosaccharide or two sugar derivativess, the number of combinations of hydroxyl, fatty acid ester and anionic group is no more than N.

In a preferred embodiment, the fatty acid ester of two sugar derivativess has 2, preferred 3, more preferably 4 or 5, most preferably 6 at least, and anionic group has 1 but no more than N-2, preferred N-3, more preferably N-4 or N-5, most preferably N-6 at least, wherein the number of combinations of fatty acid ester and anionic group is no more than N, and wherein N is the hydroxyl value that obtains the disaccharide of this derivant.

Monosaccharide derivatives of the present invention preferably has at least 2, more preferably 3 or 4 but a no more than N-1 fatty acid ester and at least one but no more than N-2, more preferably N-3 anionic group, wherein the total number of combinations of fatty acid ester and anionic group is no more than N, and wherein N is the hydroxyl value that obtains the disaccharide of this derivant.

Therefore, of the present invention, the particularly preferred monosaccharide that derives has at least one anionic group and at least two fatty acid esters, wherein the sum of anionic group and fatty acid ester is between 3-5, and the particularly preferred disaccharide that derives have at least one, preferred 1 or 4 anionic group and at least one fatty acid ester, wherein the sum of anionic group and fatty acid ester is between 6-8, and preferred 7 or 8.

Term " fatty acid " ester group used herein " or " fatty acid group " be meant by general formula-O-C (=O)-(CH ₂) _x-CH ₃, wherein x is 4 at least ,-OC (=O)-(CH ₂) _x-CH=CH-(CH ₂) _y-CH ₃, wherein x+y is 4 at least, or-O-(C=O)-(CH ₂) _X-CH=CH-(CH ₂) _y-CH=CH-(CH ₂) _z-CH ₃, wherein x+y+z represents between 2 to 20.Term used herein " anionic group " is meant electronegative part (promptly in neutral pH or use under the environment pH of this derivant electronegative).For example, such negative charge group can be sulfate radical, sulfonate radical or phosphate radical.The preferred anionic surfactants group comprises that " sulfate group " promptly has SO ₂The group of-OR general formula, " bound phosphate groups " promptly has PO ₂-(OR) ₂, wherein R is selected from atom and/or the molecule that forms univalent cation.Term " hydroxyl " is meant to have-group of OH chemical formula.

General term used herein " sugar derivatives " is meant the derivant of monosaccharide or disaccharide.

Sugar derivatives of the present invention can be used as emulsifying agent and preferentially is used for water-fast molecule.It should be noted that the stability of considering bioavailability, biologos and water insoluble molecular preparation, the complexation of water-fast molecule and sugar derivatives of the present invention provides remarkable advantages for this reason.Paired improvement can produce collaborative the improvement aspect bioavailability, biology and/or the pharmaceutical active of water insoluble molecule and the physical property (for example stability) between sugar derivatives and target molecules.Type with the counter ion character of anionic group and fatty acid ester group is the same with character, the physico-chemical property of monosaccharide of the present invention and two sugar derivativess interdependent anionic group number (and ratio) and (to) fatty acid ester group number (with hydroxy number) and becoming to littler degree.Monosaccharide derivatives of the present invention preferably has at least 1 but no more than 3 or 4 anionic group, and two sugar derivativess preferably have at least 1 but no more than 7 anionic group.

In addition, sugar derivatives height of the present invention is suitable as the adjuvant of vaccine.It should be noted that and consider bioavailability, biological activity and the stability that improves antigen component preparation, the complexation of antigen component and sugar derivatives of the present invention can provide remarkable advantages for this reason.Paired improvement can provide collaborative improvement and the enhance immunity reaction or the activating immune system of vaccine effect power and/or stability between sugar derivatives and antigen component.Term antigen component used herein is meant any component or the material of antigen itself, the for example subunit of virus, antibacterial, mycoplasma, parasite or tumor cell, microorganism, allergen, for example albumen, polysaccharide, polypeptide, glycoprotein, polysaccharide-protein conjugate, polypeptide-protein conjugate or the like or any other cause the entity of immunne response.For example, this antigen component can be by (or containing) organism or the so-called subunit of one or more organism of living, inactivation form (latter can by for example synthesize, recombinant DNA method or from organism isolating method be prepared).But term antigen component further refers to the DNA or the RNA sequence of inducing antigen (for example can be integrated into immune main body () host cell (DNA)) any component of taking place, it can be in the formation of this inducing antigen part.The vaccine that contains this nucleotide sequence also refers to dna vaccination or RNA vaccine.

Monosaccharide derivatives of the present invention preferably comes to have by oneself C ₅H ₁₀O ₅The pentose of general formula or have C by oneself ₆H ₁₂O ₆The hexose of general formula.The pentose that is fit to can be selected from arabinose, ribose, xylose.The hexose that is fit to can be selected from allolose, altriose, fructose, galactose, glucose, gulose, inositol, mannose and sorbose.This new monosaccharide derivatives is preferably from fructose, galactose or glucose.Two sugar derivativess of the present invention are preferably from having C ₁₂H ₂₂O ₁₁The disaccharide of general formula or can suitably be selected from cellobiose, gentiobiose, lactose, lactulose, maltose, 6-(.alpha.-D-galactosido)-D-glucose., sucrose and turanose.These two new sugar derivativess are preferably from lactose, maltose or sucrose.Sugar derivatives of the present invention most preferably is selected from sucrose.

Fatty acid ester group preferably has normal carbon chain, (C=O)-(CH is arranged-O- ₂) _x-CH ₃The ester group of general chemical constitution (wherein x is between 4 to 24, preferably between 4 to 22, more preferably between 6 to 18, most preferably between 6 to 14), has-O-(C=O)-(CH ₂) _X-CH=CH-(CH ₂) _y-CH ₃The ester group of universal architecture (wherein x+y is between 4 and 24, preferably between 4 and 22, more preferably between 6 and 14) or-O-(C=O)-(CH ₂) _X-CH=CH-(CH ₂) _y-CH=CH-(CH ₂) _z-CH ₃The ester group of universal architecture (wherein x+y+z is between 4 and 20, preferably between 4 and 18, more preferably between 6 and 14).The compositions of these fatty acid ester group also can exist.

Has universal architecture-O-(C=O)-(CH ₂) _x-CH ₃Preferred especially those x of fatty acid ester group be 4 (caproic acids), 6 (sad), 8 (capric acid), 10 (lauric acids), 12 (myristic acids), 14 (palmitic acid) and 16 (stearic acid).Has universal architecture-O-(C=O)-(CH ₂) _X-CH=CH-(CH ₂) _y-CH ₃Fatty acid ester group preferred those wherein x+y be 14 (for example oleic acid).Has universal architecture-O-(C=O)-(CH ₂) _X-CH=CH-(CH ₂) _y-CH=CH-(CH ₂) _z-CH ₃Fatty acid ester group preferred those wherein x+y+z be 12 (for example linoleic acids).

Anionic group preferably has O-SO ₂-OR or-PO ₂-(OR) ₂Universal architecture, wherein R be selected from form univalent cation atom and/or molecule.They comprise H ⁺, Na ⁺, K ⁺, Li ⁺Or NH ₄ ⁺Specific embodiment comprises having sulfate group O-SO ₂-OH, O-SO ₂-ONa or O-SO ₂-ONH ₄Sugar derivatives.The compositions of these sulfate groups also can exist.

The invention further relates to a kind of easy, the safe and cheap above-mentioned monosaccharide of preparation and the method for two sugar derivativess.This method comprises makes monosaccharide or disaccharide and acyl chlorides and sulfonating agent reaction.This monosaccharide or disaccharide can with said acyl chlorides and sulfonating agent with any order or reaction simultaneously.

As will be discussed in detail below, we have found that by following any method: (1) changes the character of used monosaccharide or disaccharide; (2) quantity (ratio) of the various used parent materials of change; (3) character of the used acyl chlorides of change; And/or (4) change and to be used for the cation used in the aqueous solution of purification, can obtain the prepared product of monosaccharide different, that have specific physico-chemical property or two sugar derivativess.The character of monosaccharide of so adjusting or two sugar derivativess is included in dissolubility in aqueous (water) and non-aqueous (nonpolar) solvent, form micelle and form the ability of mixed micelle with other molecule, to the absorbability of hydrophobic surface, to the absorbability of water-wetted surface, to the absorbability and the surface activity/tension active of biomaterial.

Preferred acyl chlorides is caproyl chloride, caprylyl chloride, decanoyl chloride, lauroyl chloride (lauroyl chloride), myristyl chloride (myristyl chloride), hexadecanoyl chloride (palmitin acyl chlorides), stearoyl chlorine (stearyl chloride and oleoyl chloride) and compositions thereof.

In a particular, disclosed herein is has high water-soluble, low organic solvent dissolubility, very little of hydrophobic molecule ability and very little monosaccharide or disaccharide in conjunction with the hydrophobic surface ability.In this regard, acyl chlorides is preferably selected from caprylyl chloride, decanoyl chloride, lauroyl chloride, myristyl chloride and compositions thereof.In this regard, acyl chlorides more preferably is selected from caprylyl chloride, decanoyl chloride and/or lauroyl chloride.In this regard, acyl chlorides most preferably is selected from decanoyl chloride and/or lauroyl chloride.

In another embodiment, disclosed herein is to have low water-soluble, high organic solvent dissolution, very big in conjunction with hydrophobic molecule ability and very big monosaccharide or disaccharide in conjunction with the hydrophobic surface ability.In this regard, acyl chlorides is preferably selected from lauroyl chloride, myristyl chloride, hexadecanoyl chloride, stearoyl chlorine and compositions thereof.In this regard, acyl chlorides more preferably is selected from myristyl chloride, hexadecanoyl chloride and/or stearoyl chlorine.In this regard, acyl chlorides most preferably is selected from hexadecanoyl chloride and/or stearoyl chlorine.

Preferred sulfonating agent is gasiform SO ₃, HClSO ₃(chlorosulfonic acid), SO ₃-pyridine, SO ₃-2-picoline, SO ₃-2,6-lutidines, SO ₃-dimethyl formamide, SO ₃-trimethylamine, SO ₃-triethylamine, SO ₃-dimethylaniline, SO ₃-N-ethylmorpholine, SO ₃-diethylaniline, SO ₃-dioxs and compositions thereof.The preferred SO of sulfonating agent ₃-pyridine or gasiform SO ₃

Monosaccharide or disaccharide preferably and acyl chlorides with 1: 1 to 1: the ratio between the N-1, and and sulfonating agent with 1: 1 to 1: the ratio between the N-1 is reacted, wherein the quantity of acyl chlorides ester adds that the quantity sum of sulfonating agent is no more than N, N be this derivant from monosaccharide or the hydroxyl value of disaccharide.By suitably being selected from the mol ratio between reagent, the technical staff can prepare monosaccharide or two sugar derivativess with desired fats acid esters and sulfate group number easily.

This monosaccharide or disaccharide preferably react in anhydrous thin aprotic medium with acyl chlorides and sulfonating agent.This method is preferably carried out in volume is tried one's best little organic solvent.Preferred those by for example precipitate, filtration, crystallization or evaporation, the organic solvent that can easily from compound of reaction, remove.Preferred organic is pyridine and N-crassitude.Highly preferred anhydrous dimethyl formamide and the mixture of anhydrous pyridine and the mixture of anhydrous N-crassitude and anhydrous pyridine.

If use pyridine, its consumption are preferably less than the twice of acyl chlorides consumption.More preferably, the amount of the consumption of pyridine and acyl chlorides is suitable.

For example, before reacting with sulfonating agent, monosaccharide or disaccharide might form two sugar fatty acid esters with acyl chloride reaction.

Monosaccharide or disaccharide preferably reacted preferred about 6 hours with acyl chlorides 4 to 8 hours at about 60 to 70 ℃.Subsequently, reactant mixture is kept in 18 hours in ambient temperature.Should and the reaction of sulfonating agent preferably between ambient temperature and 70 ℃, carried out at least 6 hours.In a preferred embodiment, monosaccharide or disaccharide and acyl chlorides and sulfonating agent were about 60 to 70 ℃ of reactions simultaneously at least 6 hours.

Subsequently, reactant mixture is kept in 18 hours in ambient temperature.

In another preferred embodiment, monosaccharide or disaccharide at first react in ambient temperature with acyl chlorides and with sulfonating agent, then with extremely about 50-70 ℃, preferred 55-70 ℃, more preferably from about 60 ℃ of temperature increase.

In this respect, it should be noted that this method is held at ambient temperature is meant that temperature is not very important concerning this method.This character makes this method to carry out in very wide temperature range and under condition very wide, that save very much again simultaneously.We can expect, temperature be low to moderate about 10 ℃ also be acceptable.Preferred ambient temperature is not less than 15 ℃, more preferably is not less than 18 ℃.And ambient temperature preferably is not higher than 50 ℃, more preferably no higher than 40 ℃, most preferably is not higher than 25 ℃.

Monosaccharide of the present invention or two sugar derivativess obtain with the two-step reaction of monosaccharide or disaccharide and acyl chlorides and sulfonating agent.In a preferred embodiment, this reaction is carried out with the one-step method that monosaccharide or disaccharide and acyl chlorides and sulfonating agent react simultaneously.Certainly, also might be initial by monosaccharide fatty acid ester or two sugar fatty acid esters, Surfhope SE Cosme C 1216 L-195 (Mitsubishi for example, Japan), Surfhope SE Cosme C 1216 L-595 (Mitsubishi, Japanese) or sucrose stearate S-195 (Mitsubishi, Japan), and this parent material and one or more sulfonating agent react to form required monosaccharide or two sugar derivativess.

Such as already mentioned, preferably use the least possible organic solvent amount.In this respect, preferably by heating with monosaccharide or disaccharide solvent in this organic solvent,, homogeneous solution translucent to produce.It is relatively very little or be difficult to be dissolved in the sugar of organic solvent, for example sucrose and lactose that this method for preparing homogeneous solution is particularly useful for those dissolubility in organic solvent.For these sugar being dissolved in the organic solvent of minimum or minimal volumes, temperature increases to＞and 80 ℃.The temperature of organic solvent preferably increases to＞and 90 ℃.

In an embodiment preferred, after reaction is finished, with the monosaccharide in the organic solvent or two sugar derivativess NaOH, NH ₄OH, KOH neutralize, and make it to form to have sulfate group and (comprise Na ⁺, K ⁺Or NH ₄ ⁺In the cation one) monosaccharide or two sugar derivativess.

Can make it to form two or three or how different phases (one of them is rich in this monosaccharide or two sugar derivativess) reclaims purpose monosaccharide or two sugar derivativess by cooling.This can comprise filtration, decant or the like by method well known in the art, reclaims.Remaining organic solvent can be by for example evaporating under the condition of pressure or wash with water from this and remove mutually increasing temperature and reduce.After the cooling, this organic solvent and any side-product that in reaction, forms will be present in do not contain or contain hardly any this monosaccharide or two sugar derivativess one or two mutually in.This phase or these can be removed by method known in the art (comprising filtration, decant or the like) mutually.The sugar that derives can carry out further purification by technology as known in the art.

Monosaccharide or two sugar derivativess can use and prepare that the immiscible liquid of employed organic solvent extracts in this monosaccharide or two sugar derivativess from reactant mixture.Therefore, monosaccharide or two sugar derivativess be able to side-product and preparation in the organic solvent that uses separate or separate.In this respect, the preferred volatile organic solvent of said liquid or a kind of composition of the final preparation of sugar derivatives.More preferably a kind of oil of said liquid, final preparation is a kind of emulsion.Said liquid is squalane most preferably.

These two relate to monosaccharide derivatives of the present invention and the synthetic chemical reaction of two sugar derivativess and are considered at random reaction, thereby cause producing the set of different monosaccharide or two sugar derivativess, the number difference of these monosaccharide or two sugar derivatives per molecule sulfate groups, and/or the number difference of per molecule fatty acid ester group, and therefore make that the structure that it had is also different with physicochemical properties.

Yet, it should be noted that, the quantity of the chemically different derivant in monosaccharide or the two sugar derivatives prepared products than in the above-mentioned people such as Hilgers that went through (WO96/20222, WO 967/20008) disclosed sulfonate grease-polysaccharide prepared product will be low many.If not the inclusive words of fatty acid ester group, sulfate group and the oh group distribution on two glycan molecules, then by of the present invention, in by the prepared product that disaccharide obtained with 8 oh groups, the quantity of different derivants is 28.If the inclusive words of fatty acid ester group, sulfate group and the oh group distribution on two glycan molecules,, be 3 by the quantity of the different derivants that disaccharide obtained with 8 oh groups then by of the present invention ⁸=6,561.Compare with sulfuric ester-cyclodextrin those (they are respectively 210 and 1,494,336,195), the derivant of these quantity has sizable advantage aspect its use and preparation.

Therefore, this method for preparing monosaccharide or two sugar derivativess has produced a kind of like this mixture of derivant.These derivants can be separated by using for example crystallization, precipitation, filtration, evaporation, dialysis or hyperfiltration technique.Preferably will remove employed organic emulsion carried out with formed side-product and the different monosaccharide and the separating simultaneously of two sugar derivativess of acquisition.Its preferably by be separated, the combination of chromatography, precipitation, dissolving, extraction or these technology finishes.More preferably, this monosaccharide or two sugar derivativess are separated with organic emulsion, thereby obtain dried monosaccharide or two sugar derivatives prepared products by lyophilizing.This freeze drying process preferably room temperature, intrinsic pressure be lower than less than 10mbar and cold trap under-25 ℃ the condition carry out.

Particularly, disclosed herein is the method that two sugar derivativess with certain fatty acid ester group and cation group number and type are rich in a kind of preparation, its step is to make about 1 mole disaccharide and about 7 moles, the acyl chlorides that is used for preparing each two each fatty acid ester group of glycan molecule contact and with about 1 mole, be used to prepare each sulfate group sulfonating agent or with about 1 mole, the phosphorylation agent that is used for preparing each two each phosphate ester of glycan molecule contacts, wherein the total moles of acyl chlorides and sulfonating agent is no more than N, and N is the total hydroxy of its disaccharide that contacts.

Monosaccharide of the present invention or two sugar derivatives prepared products water-soluble can increase by the following method: (1) increases the amount of employed sulfonating agent in the inventive method or phosphorylation agent and/or reduces the amount of employed acyl chlorides in the inventive method, thereby makes the monosaccharide of generation or two sugar derivativess have the more cation group number of existing relatively fatty acid ester group number.High water-soluble also can use the acyl chlorides with short carbon chain by (2), makes the monosaccharide of its product or two sugar derivatives lifes have the fatty acid ester group of relative short carbon chain.Can finish as acyl chlorides reagent by using stearoyl chlorine, decanoyl chloride, lauroyl chloride (lauroyl chloride) and/or myristyl chloride specifically.

Can make water-soluble decline or the dissolubility in non-polar solven is risen by carrying out opposite step.Can realize as acyl chlorides reagent by using lauroyl chloride (lauroyl chloride), myristyl chloride and/or stearoyl chlorine specifically.Same method can make the binding ability of monosaccharide or two sugar derivativess and hydrophobic surface strengthen.

Monosaccharide of the present invention or two sugar derivativess form amount that micellar ability can be by increasing the sulfonation used in the methods of the invention or phosphorylation agent or produce by the amount that increases acyl chlorides.Same method can make surface activity/tension active increase.

It should be noted that in this respect monosaccharide of the present invention or two sugar derivativess can form big mixed micelle with gaseous compound.For example, have been found that, monosaccharide derivatives and sulfuric ester/fatty acid ester (each monosaccharide molecule 1 sulfate group is to the ratio of 3 fatty acid ester group), or two sugar derivativess and sulfuric ester/fatty acid ester (each disaccharide molecule 1 sulfate group is to the ratio of 7 fatty acid ester group) can form the mixed micelle with polysorbate80.These micelles can not be by having the ultrafilter membrane of high molecular blocking-up.These sizes of mixed micelle with other chemical compound are according to the physical property of the ratio of hydrophilic group (being sulfuric ester) and hydrophobic group (being fatty acid ester) and institute's binding molecule and decide.

Have been found that, the prepared product that is rich in monosaccharide with some and type cation group (for example sulfate group and fatty acid ester group) or two sugar derivativess can form complex with specific and the immiscible molecule of water (for example food ingredient, dyestuff, flavoring agent, oil, drug molecule and antigen, they have the ability of temperature, reactivity, flowability and/or the bioavailability of adjusting this specific molecular).

Monosaccharide of the present invention or two sugar derivativess can be used for various medical science and pharmaceutical applications.

Monosaccharide of the present invention or two sugar derivativess, when with molecule (for example drug molecule or antigen compound) compound tense, the bioavailability of this molecule in solid, semisolid and/or the liquid preparation is improved.It also can make stability strengthen and the pot-life is improved.In addition, its secondary face that also can reduce with the molecule of its formation complex rings (toxicity).At last, its make (from insoluble medicine) uniformly, easy operating, injectable solution supply becomes possibility.

The example that the use of monosaccharide of the present invention and disaccharide (and prepared product) has the medical application aspect of very big advantage is the application in vaccine adjuvant.The adjuvant that is fit to comprises those O/w emulsions (comprising water bag squalane emulsion, water bag mineral oil emulsion, water bag hexadecane, water bag soybean oil emulsion, water bag sucrose fatty acid ester emulsion etc.), water-in-oil emulsion (comprising mineral Water-In-Oil, squalane Bao Shui, sucrose fatty acid ester Bao Shui etc.) or the water-in-oil-in-water compositions (comprising water bag mineral Water-In-Oil, water bag squalane Bao Shui, water bag sucrose fatty acid ester Bao Shui etc.) that is often referred to.

Vaccination is the cheapest method that prevents and control communicate illness of expense in people and the animal health.Vaccination or immunity comprise makes immunoreation suitable type, decorrelation antigenic component and/or antigenic determinant produce enough level and time span.This immunoreation can be by for example measuring antibody titer in the serum, proliferation of lymphocytes, anti-artificial or natural infection protection progression, guard time, reactionless number of animals or the like measure.

Many target animal species (pig for example, cattle, poultry, Canis familiaris L., cat, horse, people etc.) in, by virus, antibacterial, parasite or any other infect media (influenza virus for example, hepatitis virus, Measles virus, the vertebra poliovirus, parvovirus, rabies virus, streptococcus, meningococcus, clostridium, colon bacillus, Salmonella, Campylobacter, Actinobacillus, the Li Sita Salmonella, malaria, trypanosoma, lungworm, protozoacide, mycoplasmas, chlamydia or the like) disease that causes can be prevented or controlled by vaccination.

In most cases, anti-inactivation antigen the and also immunoreation of anti-active antigen is too low and can't set up enough protection levels or enough guard time length in some cases.Therefore, will in these antigens, add this immunoreactive adjuvant of stimulation.

Ideal adjuvant can strengthen the immunoreation (body fluid and/or cell) of the correlation type of anti-this antigen and/or the relevant protection of antigenic determinant, and does not have tangible side reaction.Stimulate the adjuvant of the type of a certain immunity may be suitable for some purposes, but be unsuitable for other purposes.Strong adjuvant for example can strengthen anti-many differences antigenic antibody-mediated and cell-mediated immunity.Adjuvant is a significant disadvantages to the antigenic different-effect of difference, especially relates to containing in the antigenic combination inoculation of several differences.There is being very strong active adjuvant to have important advantage aspect antigenic type, animal species, the immunoreation type.

The adjuvant that in DNA or RNA vaccine, uses can be in born of the same parents inducing antigen, it also preferably helps this DNA or RNA sequence successfully to be integrated into host cell DNA (transfection).

Known have many dissimilar adjuvants, but several commercially available people or veterinary vaccines of being used for are only arranged.The adjuvant type that is elected to be vaccine is determined by Several Factors, comprises the efficacy of target animal species, adjuvant, the toxicity of adjuvant, the quality of adjuvant, price of adjuvant or the like.As well known, the efficacy of adjuvant and toxicity are with relevant, and high efficacy is with high toxicity, and hypotoxicity then efficacy is also low.High toxicity is as local response, for example inflammation, swelling, abscess formation, granuloma, necrosis or the like and/or system response, for example pain, fever, hypertension, allergy, anorexia.Weight loss or the like and occur.The toxicity of adjuvant is to limit the key factor of its use, and it may then be unacceptable to other animal species can be accepted by some animal species the time.

In laboratory animal, the adjuvant of standard is the Freund Freund's complete adjuvant, and it is a kind of strong adjuvant.Because its toxic cause, especially its local effect, it can't be used in the mankind or edible animal (food animals) or companion animal (companion animals)., for example in cattle, sheep and the pig, often with mineral oil emulsion as adjuvant.For example water bag mineral oil emulsion (O/W), mineral water-in-oil emulsion (W/O) and water bag mineral water-in-oil emulsions (W/O/W).These adjuvants can produce high immunoreation (but than Freunde Freund's complete adjuvant little).The toxicity that comprises local and system's side effect is restricted their application on the companion animal and the person.In companion animal for example cat, Canis familiaris L. and Malaysia and China, use be comparatively safe adjuvant, for example ISCOM, Al (OH) ₃And polyacrylate.On the whole, these adjuvants inductive reaction lower than the mineral oil emulsion, and that serious adverse also will be low is many.On the person, aluminum salt is the adjuvant of unique permission to use.The reaction that they bring out is lower than many adjuvants that use in veterinary vaccine, and is considered to comparatively safe.

Therefore, a shortcoming of strong adjuvant is exactly that their toxicity is higher relatively.The shortcoming of safe adjuvant then is that their efficacy is relatively low.

Except efficacy and toxicity, adjuvant also is crucial with the quality that contains Adjuvanted vaccines.The standard of quality comprises viscosity, chemical stability, physical stability, materialization stability or the like.The high operation that can hinder product of viscosity, for example product is sucked syringe or with product to animals administer.The low operation that can help product of viscosity.Low chemistry, physics or materialization stability can reduce the pot-life of vaccine and need strict product storage and traffic condition.High chemistry, physics and materialization stability can make the pot-life prolong and is favourable to the logistics transportation of product.Known as people, it is high and unstable that the vaccine that contains mineral oil emulsion that uses in edible animal has viscosity.

We clearly realize that having high efficacy and hypotoxicity, resisting various antigens and maneuverable adjuvant still to have urgent demand effectively by above narration.

The invention provides such adjuvant.We have found that above-mentioned monosaccharide or two sugar derivatives height are suitable for using as adjuvant at all kinds vaccine.Therefore, the present invention also relates to adjuvant, and relate to the adjuvant prescription that preparation contains one or more said monosaccharide or two sugar derivatives vaccines with monosaccharide of the present invention or the appearance of disaccharide derivative form.This adjuvant prescription can further contain pharmaceutically acceptable carrier.For example, the carrier of Shi Heing comprises normal saline and O/w emulsion, preferred water cornerite zamene emulsion.

The invention provides the adjuvant prescription that comprises monosaccharide of the present invention or two sugar derivativess, described adjuvant prescription further contains and the immiscible solid phase of water.This adjuvant prescription also can further contain water.

By of the present invention, particularly preferred adjuvant prescription contains monosaccharide of the present invention or two sugar derivativess (I), reaches randomly water (IV) with the immiscible liquid phase of water or solid phase (II), emulsifying agent or stabilizing agent (III).Any sugar derivatives of the present invention all can be used as adjuvant and uses.For example, this derivant can be to have 1-3, preferred 1 or 2 fatty acid group and 0-3, the pentose of preferred 1 or 2 anionic group, and wherein the sum of anion and fatty acid group is no more than 4.

By of the present invention, the hexose with individual, preferred 1-3 the fatty acid group of 1-4 and individual, preferred 1-3 the anionic group (wherein the sum of anion and fatty acid group is no more than 5) of 0-4 also is particularly suitable as adjuvant and uses.

Preferably can contain 1-7, more preferably 3-7, most preferably 4-7 fatty acid group and 0-7, more preferably individual, 1-5 anionic group most preferably of 0-6 as two sugar derivativess of adjuvant, wherein the sum of anion and fatty acid group is no more than 8.

Obtained good especially result with two sugar derivativess with an anionic group, a preferred sulfate group and 5-7 fatty acid ester group.The disaccharide of deriving with 4 anionic groups, preferably sulfuric acid ester group and 4 fatty acid ester group also has very gratifying performance as adjuvant.

One or more sugar derivatives of the present invention, the concentration that exists as adjuvant in adjuvant prescription of the present invention are generally 0.1-1000g/l, preferred 0.5-500g/l, more preferably 1-320g/l.

With the immiscible liquid phase preferred oil of water.The oil that is fit to comprises, for example soybean oil, Oleum Arachidis hypogaeae semen, canola oil, olive oil, safflower oil, Semen Maydis oil, mazola oil, cod liver oil, almond oil, Oleum Gossypii semen, ethyl oleate, isopropyl myristate, palmitic acid isopropyl ester, mineral oil, myristyl alcohol, octyldodecanol (octyldodecanol), almond oil, Oleum sesami, oleic acid myristin, cetyl oleate (cetyl oleate) and palmitic acid myristin.Other oil that is fit to comprises by saturated, undersaturated and/or partially hydrogenated fatty acid silicon-based oil, artificial oil (triglyceride of forming by saturated and unsaturated C12-C24 fatty acid chain for example, for example oleic triglyceride, terpenes, linolene, the angle Squalene, squalane, squalamine) and fluorinated oil (comprise and be called FC-40, FC-43, FC-72, FC-77, FC-70, the perfluoro-compound of FC-75, perflexane, perfluoro-octyl bromide (perfluorooctylbromide) (also being perfluorobron), the biological affine oil that PFO iodine or its mixture are formed.

Obtained good result with a kind of adjuvant prescription that is squalane, angle Squalene, mineral oil, vegetable oil, hexadecane, fluorocarbon or silicone oil with water immiscible mutually (II).

Usually being present in the adjuvant prescription is 0-640g/l with do not dissolve each other the mutually concentration of (II) of water, preferred 0-480g/l, more preferably 10-320g/l.

If this adjuvant prescription contains and the immiscible solid phase of water (II), the preferred water-fast salt of this solid phase so.Particularly suitable is insoluble aluminum or calcium salt or its mixture.Preferred salt comprises aluminium hydroxide, aluminum phosphate, calcium phosphate silicon dioxide and composition thereof.

The stabilizing agent of emulsifying agent (III) can be a detergent.Suitable emulsifying and/or stabilisation reagent comprise, for example, cholesterol, diethanolamine, glyceryl monostearate, lanolin alcohol, lecithin, list and two glyceride, monoethanolamine, oleic acid, oleyl alcohol, (for example poloxamer 188 for poloxamer, poloxamer 184, poloxamer 181), non-ionic block copolymer (for example PLURONICS of BASF), polyoxyethylene 50 stearic acid, polyoxyl 35 Oleum Ricini, polyoxyl 10 oily alkene ethers, polyoxyl 20 cetostearyl ethers, polyoxyl 40 stearic acid, Spheron MD 30/70 20, multi-sorbitol ester 40, multi-sorbitol ester 60, PS, propylene-glycol diacetate, propylene glycol monostearate, sodium lauryl sulfate, sodium stearate, the mono laurate sorbitol ester, single oleic acid sorbitol ester, single palmitic acid sorbitol ester, the monostearate sorbitol ester, stearic acid, Triton X-100, saponin, pure saponin, (for example QS21), polymer (for example polyacrylate).

With a kind of emulsifying agent or stabilizing agent (III) is that the adjuvant prescription of nonionic detergent (the hydrophil lipophil balance value is greater than 10), sugar fatty acid ester or anionic detergent (the hydrophil lipophil balance value is greater than 10) has been obtained extraordinary result.

Preferred solvent or stabilizing agent (III) comprise many sorbitol 20, many sorbitol 80, many sorbitol 85, Triton-X 100, saponin, lecithin, non-ionic block copolymer, sucrose fatty acid ester, sugared laurate (for example Ryoto sugar ester 1695 of Mitsubishi-Kagaku Food Co., Ltd).Particularly preferably be many sorbitol 80 and sucrose fatty acid ester.

Monosaccharide of the present invention or disaccharide also can be preferentially as emulsifying agent or stabilizing agents (III) in the adjuvant prescription.With having at least 3, preferred at least 4 the no more than N-1 of list anionic groups and at least 1 but no more than N-3, preferred for not obtained good especially result in the monosaccharide of N-4 fatty acid ester group or two sugar derivativess (wherein N derives this monosaccharide of this derivant or the hydroxyl value of disaccharide, and the number of combinations of fatty acid and anionic group to be no more than N individual) being arranged.

Usually be present in one or more emulsifying agent in the adjuvant prescription of the present invention or stabilizing agent volume total concentration and be 0 to 640g/l, preferred 1-480g/l, more preferably 1-320g/l.

The water (IV) that is fit to comprises, for example saline, phosphate buffered saline(PBS), citric acid buffer salt solution, etc. ooze solion, etc. ooze non-ionic solution or the like.The amount of water can in very large range change, usually from 0 to 999.9g/l, preferred 10-990g/l, more preferably 640-990g/l.

The invention still further relates to vaccine optimum, that contain antigen compound and monosaccharide of the present invention or two sugar derivativess in adjuvant prescription of the present invention.This vaccine can contain 0.05-250g/l, preferred 0.25-125g/l, more preferably the mixture of the monosaccharide of 1-80g/l or two sugar derivativess or this derivant is as adjuvant.It can contain again one or more total concentration from 0 to 640g/l, preferred 1-480g/l, more preferably the emulsifying agent of 1-320g/l or stabilizing agent and a kind of concentration be 0 to 640g/l, preferred 1-480g/l, more preferably 1-320g/l with the water liquid phase (preferred oil) of not dissolving each other.

This vaccine can contain aforesaid any antigen component.For the preparation of this vaccine, its antigen component or just mixed or just mix before use before use.

For example, vaccine of the present invention can be used for the immunity (latter for example comprises mammal, bird and rodent for example pig, cattle, sheep, horse, Canis familiaris L., cattle and poultry) of humans and animals.

This vaccine, adjuvant or adjuvant prescription can be by parenteral or parenteral approach, for example intramuscular, Intradermal, percutaneous, subcutaneous, endoperitoneal, Intradermal, intranasal, nose, mouthful, in intravaginal, the cloaca or the like, use.

It should be noted that the present invention has also indicated the purposes of a kind of known adjuvant and the compositions of the adjuvant that occurs with monosaccharide of the present invention or two sugar forms.

For edible animal, adjuvant of the present invention is with the advantage of the adjuvant comparison that has been applied, for example local and system's side effect is less, less to the uncomfortable degree of animal inoculation vaccine, since reduced mortality influence by body weight profit animal make economic loss less, because contain that the meat loss of residual vaccine makes that economic loss danger less, that the vaccine administration person is injected automatically is lower, ease for operation raising of vaccine, the stability raising of product or the like.

For companion animal, adjuvant of the present invention and advantage that be applied, known adjuvant comparison be, for example immunoreactive level is higher, the raising of immune time, reply size of animal raising, can be more or the like with the antigen of this adjuvant combination.

The present invention will further set forth by following, non-limiting example.

Embodiment

Some experiments of describing among the following embodiment are carried out simultaneously.For ease of relatively, each embodiment is to having listed selected group result.The result that matched group importantly, is arranged in several embodiment.

Embodiment #1

As the front to (Hilgers etc., 1986) as described in so-called sulfuric ester-polysaccharide, synthesis of sucrose derivant.Briefly, by 90 ℃,＜the 50mbar condition under heating and add anhydrous N-N-methyl 2-pyrrolidone N-(NMP; Merck) and anhydrous pyridine (Merck), (Merck) carries out drying to fine-powdered sucrose.With mixture in 80 ℃ of stirrings until obtaining settled solution.Add lauroyl chloride (Merck), and reactant mixture was kept about 6 hours in 60 ℃.Add SO ₃-pyridine (Merck), and reactant mixture bathed about 18 hours in the room temperature temperature.With 4M NaOH its pH is transferred to 7.0 (± 0.3).With increase temperature (＜80 ℃), reduce pressure (＜10mbar) method carry out the popularity evaporation (＞6h), and in 4 ℃ of condensations, till the residual loss in weight was less than 0.1g/30 minute, to remove N-N-methyl 2-pyrrolidone N-and pyridine.The amount of the employed parent material of different derivants is listed in table #1.1.

Table #1.1

Sucrose derivative	Sucrose	Lauroyl chloride	The SO3-pyridine	NMP	Pyridine	Molar ratio
									(g )	(g)	(g)	(g)	(g)	L/ sucrose	S/ sucrose
(lauroyl) 7-sucrose	6.8	30.7	0.0	30.1	15.8	7.0	0.0
								(sulfuric ester) 1-(lauroyl) 7-sucrose	6.8	30.7	3.2	30.1	15.8	7.0	1.0
(lauroyl) 5-sucrose	6.8	21.9	0.0	30.1	15.8	5.0	0.0
								(sulfuric ester) 1-(lauroyl) 5-sucrose	6.8	21.9	3.2	30.1	15.8	5.0	1.0
(lauroyl) 3-sucrose	6.8	13.1	0.0	30.1	15.8	3.0	0.0
								(sulfuric ester) 1-(lauroyl) L3-sucrose	6.8	13.1	3.2	30.1	15.8	3.0	1.0
(lauroyl) 1-sucrose	6.8	4.4	0.0	30.1	15.8	1.0	0.0
								(sulfuric ester) 1-(lauroyl) 1-sucrose	6.8	4.4	3.2	30.1	15.8	1.0	1.0

# molar ratio: L/ sucrose: the lauroyl chloride molal quantity of every mole of sucrose; S/ sucrose: the SO of every mole of sucrose ₃-pyridine molal quantity.

By thin layer chromatography (TLC) product that obtains is analyzed.0.5g derivant sample is dissolved in 4.5ml NMP, and every kind of solution of gained is got 2 μ l points (HPLC-TLC, normal phase on the TLC silica gel plate; Anatech, Newark; DElaware; The U.S.) also use the mixture of 233ml diethyl ether+100ml normal hexane+3.3ml acetic acid to launch.Spray this silica gel plate and in 120 ℃ of heating 10-30 minute, so that the speckle on the plate is developed the color with the sulfuric acid solution of the 50%v/v that is dissolved in methanol.The results are shown in figure #1.

The prescription of the different sucrose derivatives of table among the #1.1 is by 10g sucrose derivative and 10g PS (ICI), 40g squalane (Merck), 190g 0.01w/v% thimerosal (Sigma) phosphate buffered saline(PBS) (PBS-thimerosal; PH 7.0) mixed.Intrinsic pressure under ambient temperature, with at least 400 crust carries out emulsifying by Y110 type Micro Fluid device (Microfluidics company, Newton, the U.S.) to each mixture of gained three times.In microscopically each emulsion is detected.If at the microscopically that amplifies 1000 times, to be inspected the Yezhong and had for per 10 more than the oil droplet of 10 diameters greater than 1 μ m, that just repeats this emulsion process.The emulsion of gained is stored in 4 ℃ until use.

On one's body the adjuvant vigor of these preparations is measured pig.With (as described in people such as Hulst (1994)), 32 μ g/ml typical case swine fever virus glycoprotein E, the 2 (CSFV-E2 that produce by insect cell containing of the choice preparation of a volume and a volume; ID-DLO, Lelystad, Holland) antigen preparation mixed vaccine.

Five pigs are one group (10 age in week), carry out the intramuscular injection immunity with 2ml vaccine/head.After three weeks, repeat immunity with same vaccine.After three weeks, measure the antibody titer of anti-CSFV-E2 in the serum at secondary immunity with described virus neutralization tests such as Terpstra (microorganism veterinary, 1984,9,113-120 page or leaf).Calculate every group geometric mean titer (GMT), standard deviation (STDEV) and antilogarithm (2 rank GMT).The results are shown in table 1.2.

In this animal experiment, comprised sulfuric ester-cyclodextrin/water bag squalane emulsion (SL-CD/ squalane/PS; Hilgers etc., vaccine, 1999,17,219-228 page or leaf).

Table 1.2

Group	Vaccine		Strengthen 2-log CSFV-NAT in 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.32	0.00	10
						2	CSFV-E2	Squalane/PS [160/40]	3.84	1.12	14
3	CSFV-E2	(lauroyl) 7-sucrose/squalane/PS [40/160/40]	10.36	1.35	1,311
						4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	14.47	0.78	22,739
5	CSFV-E2	(lauroyl) 5-sucrose/squalane/PS [40/160/40]	10.24	2.29	1,208
						6	CSFV-E2	(sulfuric ester) 1-(lauroyl) 5-sucrose/squalane/PS [40/160/40]	11.07	1.72	2,154
7	CSFV-E2	(lauroyl) 3-sucrose/squalane/PS [40/160/40]	11.56	1.82	3,011
						8	CSFV-E2	(sulfuric ester) 1-(lauroyl) 3-sucrose/squalane/PS [40/160/40]	11.16	1.57	2,282
9	CSFV-E2	(lauroyl) 1-sucrose/squalane/PS [40/160/40]	9.39	1.90	671
						10	CSFV-E2	(sulfuric ester) 1-(lauroyl) 1-sucrose/squalane/PS [40/160/40]	9.91	0.00	960
11	CSFV-E2	SL-CD/ squalane/PS	13.36	1.56	10,484

The GMT=geometric mean titer, the meansigma methods of promptly single on the same group animal 2 logarithm titres;

STDEV: standard deviation; Antilogarithm=2 time powers (GMT).

Embodiment #2

34.2g (0.1 mole) anhydrous sucrose (Merck), the anhydrous N-methyl-pyrrolidone of 149g (1.5 moles) and 79g (1 mole) anhydrous pyridine are placed in the round-bottomed flask, then it are linked rotary evaporator ^TM(Buchi, Switzerland) goes up rotation and mixes.With this mixture heated to 90 ℃ until obtaining clear solutions.Then temperature is transferred to 60 ℃ and in this sucrose solution, add the lauroyl chloride of 153.3g (0.7 mole).Reactant mixture in the flask was kept 6 hours in 60 ℃.Add 15.9g (0.1 mole) SO in the reactant mixture in flask ₃-pyridine, and with 60 ℃ kept 6 hours, kept 12 hours with ambient temperature then.This reactant mixture was kept 24 hours in 4 ℃, thereby form crystal settling and two liquid phases.In the collection mutually and in rotary evaporator ^TMGo up that (＜10mbar) method is evaporated, and in 4 ℃ of condensations, till the residual loss in weight was less than 0.1g/30 minute, to remove desolvate (component I) to increase temperature (＜60 ℃), to reduce pressure.In the sample of component I, add normal hexane and N-N-methyl 2-pyrrolidone N-.Thereby this mixture was formed phase (component II) on the yellow transparent, milky intermediate phase (component III) in centrifugal 10 minutes with transparent mutually following in 1000g.In rotary evaporator ^TMGo up that (＜10mbar) method is evaporated, and in 4 ℃ of condensations, till the residual loss in weight was less than 0.1g/30 minute, to remove the solvent of component II and component III to increase temperature (＜60 ℃), to reduce pressure.

By the TLC described in the embodiment 1 product of gained is analyzed.

Prepare several preparations and measure their antibody responses CSFV-E2 by the method described in the foregoing description 1.The results are shown in table #2.2.

Get this sucrose derivative each component (component I, component II and component III) each 10g and 10g PS (ICI), 40g squalane (Merck) and 190g PBS-thimerosal, prepare preparation by the method described in the embodiment #1.These preparations are respectively at detecting in the group 3,6 and 18.

Prepare (sulfuric ester) 1-(lauroyl) the 7-sucrose among the 10g embodiment #1 and the preparation of 10g PS, 40g squalane and 190g PBS-thimerosal by the method described in the embodiment #1.Said preparation detects in group 2 and 5.

Prepare (sulfuric ester) 1-(lauroyl) the 7-sucrose among the 10g table #1.1 and the preparation of 10g PS, 10g squalane and 220g PBS-thimerosal by the method described in the embodiment #1.Said preparation detects in group 4.

Prepare the preparation that (sulfuric ester) 1-(lauroyl) 7-sucrose among the 10g sucrose derivative table #1.1 and 10g PS and 230g do not have squalane PBS-thimerosal by the method described in the embodiment #1.Said preparation detects in group 7.

The preparation for preparing 10g PS, 40g squalane (Merck) and 200g PBS-thimerosal by the method described in the foregoing description #1.Said preparation detects in group 9.

This experiment has comprised a kind of mineral oil bag water logging water CSFV-E2 vaccine (ID-Lelystad, Lelystad, Holland), its positive contrast.Said preparation detects in group 10.

Table #2.2

Group	Vaccine		Strengthen 2-log CSFV-NAT in 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	4.2	0.7	18
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose (embodiment # 1)/squalane/PS [40/160/40]	11.1	0.4	2,228
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose component-I/ squalane/PS [40/160/40]	8.2	0.7	285
						4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose (embodiment # 1)/squalane/PS [40/40/40]	10.7	0.9	1,689
5	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose (embodiment # 1)/squalane/PS [40/160/40]	≥11.3	0.0	≥2,560
						6	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose component-II/ squalane/PS [40/160/40]	8.4	0.9	347
7	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose (embodiment # 1)/PS [40/40]	9.3	2.1	619
						8	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose component-III/ squalane/PS	≥11.3	0.0	≥2,560
9	CSFV-E2	Squalane/PS [160/40]	8.3	1.3	309
						10	CSFV-E2	Water logging water bag mineral oil emulsion	≥11.3	0.0	≥2,560

This water logging water bag mineral oil emulsion is available from ID-Lelystad, Lelystad, Holland.

Except antibody response, carry out the lymphopoiesis analysis with peripheral blood lymphocytes (PBMC) and come in these adjuvants some are measured in the effect aspect the cell-mediated immunoreation.After the secondary immunity 6 days, from organize 1, group 2 and organize every pig of 10 and collect the 12ml heparinemia on one's body.PBS with 3 times of volumes dilutes this blood sample and coating on the Ficoll-Paque of 12ml 50-ml polypropylene tube (Falcon) lining (Pharmacia, Uppsala, Sweden).With 1000g centrifugal 20 minutes, collect then contain the interface of PBMC and with PBS with cell washing twice, then to this suspension in the centrifugal 10-15 of 1000g minute.Measure viable count by the trypanblue exclusion method that amplifies 100 times, and suspension is adjusted to 5 * 10 ⁶Cell/ml medium [adding RPMI 1640 media (Flow10-601-22) of 100IE/ml penicillin, 0.1mg/ml streptomycin, 4 μ l beta-mercaptoethanol/L and 10% normal pig serum].With the sample of 100 μ l in each suspension with in 6 times of holes that are placed on flat 96 orifice plates.With 50 μ lRPMI media three copies are added (negative control), and three copies are added with 50 μ l, 7.1 μ g CSFV-E2/ml medium solutions.With cell in 37 ℃, 5% CO ₂(in CO ₂In the incubator) cultivated 4 days under the condition.After the cultivation, in each hole, add 25 μ l and contain 50 μ Ci methyl 3H-thymidines (AmershamTRA 120; 1mCi/ml)/medium of ml medium.Cultivate after 4 hours, the DNA that uses cell harvesting machine (Tomtec Harvester 96 match IIIM) to go up pair cell at filter (Wallac) collects.In 70 ℃ filter is carried out drying and places it in (Wallac) in the filter bag.Add 5ml scintillation solution (Wallac bataplate scint; Wallac, Turku, Finland) and sack sealed, (Wallac 1450 type Microbeta PLUS β-computers Wallac) are measured the radioactivity of each sample with β-computer.Deduct average with the average (cmp) of 2 or 3 copy per minute numbers only cultivating with medium, calculate the stimulation index of each animal lymph cell suspension with 2 or 3 copy per minute numbers of antigenic stimulus.Calculate the mathematical mean (AMT) and the standard deviation (STDEV) thereof of every treated animal stimulation index.The results are shown in table #2.3.

Table #2.3

Group	Vaccine		Stimulation index (cpm)
						Antigen	Adjuvant prescription	ATM	STDEV
1	CSFV-E2	No adjuvant	1,993	448
					2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose (embodiment #1)/squalane/PS [40/160/40]	27,081	16,236
10	CSFV-E2	Mineral Water-In-Oil/PS	2,384	1,174

Embodiment #3

As described in embodiment #1, synthetic various sucrose derivatives.By 90 ℃,＜the 50mbar condition under heating 6 hours and add anhydrous N-N-methyl 2-pyrrolidone N-(Merck) and anhydrous pyridine (Merck), (Merck) carries out drying to fine-powdered sucrose.With mixture in 80 ℃ of stirrings until obtaining settled solution.Add lauroyl chloride (Merck), myristyl chloride (Merck), hexadecanoyl chloride (Merck) or stearoyl chlorine (Merck), and reactant mixture was bathed 6 hours in 60 ℃ of temperature.Add SO ₃-pyridine (Merck), and reactant mixture bathed 18 hours in the room temperature temperature.This reactant mixture in 4 ℃ of maintenances 24 hours, is made its formation two or three-phase.Phase in the collection, and to increase temperature (＜60 ℃), to reduce pressure (＜10mbar) method is evaporated, and in 4 ℃ of condensations, till the residual loss in weight was less than 0.1g/30 minute, to remove N-N-methyl 2-pyrrolidone N-and pyridine.

The amount of employed parent material is listed in table #3.1.

Table #3.1

Sucrose derivative	Sucrose	Acyl chlorides		SO 3-pyridine	NMP	Pyridine	Molar ratio
										(g)	(g)	(type)	(g)	(g)	(g)	L/ sucrose	S/ sucrose
									(lauroyl) 7-sucrose	6.8	30.7	Lauroyl chloride	0.0	30	16	7.0	0.0
(sulfuric ester) 0.5-(lauroyl) 7-sucrose	6.8	30.7	Lauroyl chloride	1.6	30	16	7.0	0.5
									(sulfuric ester) 0.5-(lauroyl) 7-sucrose	6.8	34.6	Lauroyl chloride	3.2	30	16	7.0	1.0
(myristoyl) 7-sucrose	6.8	34.6	Myristyl chloride	0.0	30	16	7.0	0.0
									(sulfuric ester) 0.5-(myristoyl) 7-sucrose	6.8	34.6	Myristyl chloride	1.6	30	16	7.0	0.5
(sulfuric ester) 1-(myristoyl) 7-sucrose	6.8	34.6	Myristyl chloride	3.2	30	16	7.0	1.0
									(palmityl) 7-sucrose	6.8	38.5	Hexadecanoyl chloride	0.0	30	16	7.0	0.0
(sulfuric ester) 0.5-(palmityl) 7-sucrose	6.8	38.5	Hexadecanoyl chloride	1.6	30	16	7.0	0.5
									(sulfuric ester) 1-(palmityl) 7-sucrose	6.8	38.5	Hexadecanoyl chloride	3.2	30	16	7.0	1.0
(stearoyl) 7-sucrose	6.8	42.4	Stearoyl chlorine	0.0	30	16	1.0	0.0
									(sulfuric ester) 0.5-(stearoyl) 7-sucrose	6.8	42.4	Stearoyl chlorine	1.6	30	16	1.0	0.5
(sulfuric ester) 1-(stearoyl) 7-sucrose	6.8	42.4	Stearoyl chlorine	3.2	30	16	1.0	1.0

# molar ratio: L/ sucrose: the acyl chlorides molal quantity of every mole of sucrose; S/ sucrose: the SO of every mole of sucrose ₃-pyridine molal quantity.

By the TLC method described in the foregoing description #1 the product of some acquisitions is analyzed.

Prepare the sucrose derivative among the 10g table #3.1 and the preparation of 10g PS (ICI), 40g squalane (Merck) and 190g PBS-thimerosal by the method described in the foregoing description #1.

Described in above-mentioned embodiment #1, measure several in these preparations on one's body in the effect aspect the anti-CSFV-E2 immunoreation pig.Press the antibody titer that anti-CSFV in the serum is measured in the virus neutralization tests described in the foregoing description #1.The results are shown in table #3.2.

In addition, measure the antibody titer of anti-CSFV by elisa (ELISA).For this reason, assign in each hole by the carbonic acid buffer (pH 9.6) that 50 μ l is contained the pure CSFV-E2 of 2.5 μ g/ml immune affinity chromatographics elisa plate is coated with, bathed 18 hours or 37 ℃ of temperature were bathed 2 hours in 4 ℃ of temperature then.With the dull and stereotyped washing of 20 couples of 0.02%Tween 5 times, and be dissolved in phosphate buffer (PBS with 200 μ l/ holes; PH 7.2; 0.05M) in 2% (w/v) skim milk (Difco) seal, bathed 1 hour in 37 ℃ of temperature then.With the PBS (PBS/SM) that contains 2% (w/v) skim milk to 10 or 100 times of the pre-dilutions of blood serum sample, and on the ELISA flat board with PBS/SM in order to the pre-diluted twice of 50 μ l.Next, bathed dull and stereotyped 1 hour in 37 ℃ of temperature.After with 5 circulations of 0.02%Tween 20 washings, Xiang Kongzhong adds 50 μ l and contains and peroxidase (Dako; Dilute by manufacturers instruction) the anti-pig Ig of conjugated rabbit antiserum PBS/SM, and in 37 ℃ once more temperature bathed these flat boards 1 hour.With dull and stereotyped 10 times of 0.02%Tween 20 washing, and Xiang Kongli adds 100 μ l and contains 2,2 '-aziono-two-[3-ethyl-benzthiazoline sulfonic acid (ABTS)+H ₂O ₂(kirkegaard ﹠amp; Perry Labs, Inc., Gaithersburg, substrate solution MA).Flat board was bathed 1 hour and was measured with Titertek Multiscan (ICN/Flow, Oxfordshire, Britain) absorption of 405nm in 20 ℃ of temperature.(it has provided the optimal population that is higher than 1 absorbance units of background value in ELISA to antibody titer to the absorption value that is equivalent to the serum samples diluted factor with the degeneration factor of serum-concentration curve chart linear segment; Linearisation between the absorption value 0.0 to 1.4 is very obvious) represent.Table #3.3 and #3.4 have listed the antibody titer after 3 weeks of enhance immunity and 12 weeks respectively.

Measure the effect of the anti-CSFV-E2 of these preparation pair cell mediations by method described in the foregoing description #2.The results are shown in table #3.5.

Table #3.2

Group	Vaccine		Strengthen 2-log CSFV-NAT in 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.4	1.2	11
						2	CSFV-E2	(myristoyl) 7-sucrose/squalane/PS [40/160/40]	9.8	2.6	916
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose component-I/ squalane/PS [40/160/40]	14.9	0.5	31,042
						4	CSFV-E2	(sulfuric ester) 1-(myristoyl) 7-sucrose/squalane/PS [40/40/40]	13.3	2.8	10,240
5	CSFV-E2	(sulfuric ester) 1-(palmityl) 7-sucrose/squalane/PS [40/160/40]	10.0	2.1	993

Table #3.3

Group	Vaccine		2-log resists-E2 ELISA antibody titer in enhancing 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	5.53	1.2	46
						2	CSFV-E2	(myristoyl) 7-sucrose/squalane/PS [40/160/40]	11.05	1.7	2,120
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose component-I/ squalane/PS [40/160/40]	13.78	1.2	14,067
						4	CSFV-E2	(sulfuric ester) 1-(myristoyl) 7-sucrose/squalane/PS [40/40/40]	13.05	2.1	11,585
5	CSFV-E2	(sulfuric ester) 1-(palmityl) 7-sucrose/squalane/PS [40/160/40]	11.24	1.2	2,419

Table #3.4

Group	Vaccine		2-log resists-E2 ELISA antibody titer in enhancing 12 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	0.89	0.8	2
						2	CSFV-E2	(myristoyl) 7-sucrose/squalane/PS [40/160/40]	4.80	1.6	28
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose component-I/ squalane/PS [40/160/40]	7.69	1.8	207
						4	CSFV-E2	(sulfuric ester) 1-(myristoyl) 7-sucrose/squalane/PS [40/40/40]	6.51	2.0	91
5	CSFV-E2	(sulfuric ester) 1-(palmityl) 7-sucrose/squalane/PS [40/160/40]	4.94	1.0	31

Table #3.5

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	ATM	STDEV	ATM	STDEV
							1	CSFV-E2	No adjuvant	2,216	556	3,468	2,657
2	CSFV-E2	(myristoyl) 7-sucrose/squalane/PS [40/160/40]	3,872	3,336	17,195	11,664
							3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	8,306	5,943	22,018	28,194
4	CSFV-E2	(sulfuric ester) 1-(myristoyl) 7-sucrose/squalane/PS [40/160/40]	4,629	5,939	10,693	9,707
							5	CSFV-E2	(sulfuric ester) 1-(palmityl) 7-sucrose/squalane/PS [40/160/40]	3,100	4,400	15,413	22,485

Measured the antibody response effect of several preparations in anti-inactivation influenza virus H1N1 strains A/Swine and H3N2 bacterial strain MRC-11 (below be called A/Swine and MRC-11 respectively) and anti-inactivation pseudorabies virus (PRV) serum on one's body pig.With the 4.4 μ g A/Swine, the 4 μ g MRC-11 and 10 that have or do not have adjuvant ^8.3Inactivation PRV (Fort DodgeAnimal Health Holland, Weesp, the Holland of TCID 50 (TCID 50 is that born of the same parents cause the dosage that 50% tissue culture infects outward); Hilger etc., vaccine 1994) in 0 week with 3 weeks animal was injected.After three weeks of immunity (3 week) for the first time and after immunity (6 week) three weeks for the second time, measure the antibody response of anti-A/Swine and MRC-11 with ELISA., be distributed in each hole for this reason, elisa plate be coated with, bathed 18 hours or 37 ℃ of temperature were bathed 2 hours in 4 ℃ of temperature then in order to the influenza virus of saccharose gradient purification by the carbonic acid buffer (pH 9.6) that 50 μ l is contained 5 μ g HA/ml.To flat board washing 5 times, and be dissolved in phosphate buffer (PBS with 0.02%Tween20 with 200 μ l/ holes; PH 7.2; 0.05M) in 2% (w/v) skim milk (Difco) seal, bathed 1 hour in 37 ℃ of temperature then.With the PBS (PBS/SM) that contains 2% (w/v) skim milk to 10 or 100 times of the pre-dilutions of blood serum sample, and on the ELISA flat board with PBS/SM in order to the pre-diluted twice of 50 μ l.Next, bathed dull and stereotyped 1 hour in 37 ℃ of temperature.After with 5 circulations of 0.02%Tween 20 washings, Xiang Kongzhong adds 50 μ l and contains and peroxidase (ID-Lelystad; Carry out 1/2000 dilution in PBS/SM) conjugated mouse-anti pig total IgG monoclonal antibody, and in 37 ℃ once more temperature bathed these flat boards 1 hour.With dull and stereotyped 10 times of 0.02%Tween 20 washing, and Xiang Kongli adds 100 μ l and contains 2,2 '-azine-two-[3-ethyl-benzothiazole sulfonate moiety (ABTS)+H ₂O ₂(Kirkegaard ﹠amp; Perry Labs, Inc., Gaithersburg, substrate solution MA).Flat board was bathed 60 minutes and was measured with Titertek Multiscan (ICN/Flow, Oxfordshire, Britain) absorption of 405nm in 20 ℃ of temperature.(it has provided the optimal population that is higher than 1 absorbance units of background value in ELISA to antibody titer to the absorption value that is equivalent to the serum samples diluted factor with the degeneration factor of serum-concentration curve chart linear segment; Linearisation between the absorption value 0.0 to 1.4 is very obvious) represent.Table #3.6 and #3.7 have listed first immunisation (basis) and the antibody titer of secondary immunity (increase) after 3 weeks respectively.

In 6 weeks, measure the antibody response of anti-iPRV with (vaccine, 1994,12,653-660 page or leaf) described virus neutralization tests such as Hilgers.The results are shown in table #3.8.

Measure the resisiting influenza virus H1N1 strains A/Swine of these preparation pair cell mediations and the immunne response of H3N2 bacterial strain MRC-11 by method described in the foregoing description #2 on one's body pig.It is that the A/Swine and the MRC-11 of 0.5 and 1.5 μ g HA/ml cell culture mediums excites that PBMC is subjected to concentration.The result lists in table #3.9 and #3.10 respectively.

Table #3.6

Group	Vaccine		The antibody titer of 2-log A/Swine ELISA in first immunisation 3 all backs serum			The antibody titer of 2-log A/Swine ELISA in enhance immunity 3 all backs serum
										Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm	GMT	STDEV	Antilogarithm
1	A/Swine+ MRC-11	No adjuvant	4.26	0.6	19	7.69	1.3	207
									2	A/Swine+ MRC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	9.14	1.4	564	12.03	1.5	4,182
3	A/Swine+ MRC-11	Water bag mineral oil emulsion (Suvaxyn; FDAHH)	8.09	1.1	272	10.44	0.8	1,389

Table #3.7

Group	Vaccine		The antibody titer of 2-log MRC-11 ELISA in first immunisation 3 all backs serum			The antibody titer of 2-log MRC-11 ELISA in enhance immunity 3 all backs serum
										Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm	GMT	STDEV	Antilogarithm
1	A/Swine+ MRC-11	No adjuvant	6.97	0.9	125	10.30	1.1	1,260
									2	A/Swine+ MRC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	11.30	1.0	2,521	14.16	1.3	18,306
3	A/Swine+ MRC-11	Water bag mineral oil emulsion (Suvaxyn; FDAHH)	10.55	0.8	1,499	12.93	1.1	7,806

Table #3.8

Group	Vaccine		In the enhance immunity 3 week back serum 2-log anti--NAT of PRV
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	A/Swine+ MRC-11	No adjuvant	0.00	0.00	1
						2	A/Swine+ MRC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	5.03	1.4	33
3	A/Swine+ MRC-11	Water bag mineral oil emulsion (Suvaxyn; FDAHH)	4.07	2.0	17

Table #3.9

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	ATM	STDEV	ATM	STDEV
							1	A/Swine+ MRC-11	No adjuvant	15,485	23,017	26,242	26,526
2	A/Swine+ MRC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	8,287	7,940	35,467	13,637
							3	A/Swine+ MRC-11	Water bag mineral oil emulsion (Suvaxyn; FDAHH)	4,312	3,298	21,467	14,822

Table #3.10

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	ATM	STDEV	ATM	STDEV
							1	A/Swine+ MRC-11	No adjuvant	12,186	15,108	27,571	27,320
2	A/Swine+ MRC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	15,300	18,333	48,117	40,758
							3	A/Swine+ MRC-11	Water bag mineral oil emulsion (Suvaxyn; FDAHH)	4,527	3,287	19,882	18,894

Embodiment #4

Described in embodiment #3, synthetic various sucrose derivatives.The amount of employed parent material is listed in table #4.1.

Table #4.1

Sucrose derivative	Sucrose	Acyl chlorides		SO 3-pyridine	NMP	Pyridine	Molar ratio
										(g)	(g)	Type	(g)	(g)	(g)	L/ sucrose	S/ sucrose
									(lauroyl) 8-sucrose	6.8	35.0	Lauroyl chloride	0.0	30	16	8.0	0
(sulfuric ester) 0.5-(lauroyl) 7-sucrose	6.8	30.7	Lauroyl chloride	1.6	30	16	7.0	0.5
									(sulfuric ester) 1-(lauroyl) 6-sucrose	6.8	26.3	Lauroyl chloride	3.2	30	16	6.0	1.0
(sulfuric ester) 1.5-(lauroyl) 5-sucrose	6.8	21.9	Lauroyl chloride	4.8	30	16	5.0	1.5
									(sulfuric ester) 2-(lauroyl) 4-sucrose	6.8	17.5	Lauroyl chloride	6.4	30	16	4.0	2.0
(sulfuric ester) 2.5-(lauroyl) 3-sucrose	6.8	13.1	Lauroyl chloride	8.0	30	16	3.0	2.5
									(sulfuric ester) 3-(lauroyl) 2-sucrose	6.8	8.8	Lauroyl chloride	9.4	30	16	2.0	3.0
(sulfuric ester) 3.5-(lauroyl) 1-sucrose	6.8	4.4	Lauroyl chloride	11.0	30	16	1.0	3.5
									(sulfuric ester) 4-sucrose	6.8	0.0	Lauroyl chloride	12.6	30	16	0.0	4.0

# molar ratio: L/ sucrose: the dodecanoyl chlorine molal quantity of every mole of sucrose; S/ sucrose: the SO of every mole of sucrose ₃-pyridine molal quantity.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

Prepare the sucrose derivatives different among the 10g table #4.1 and the preparation of 10g PS (ICI), 40g squalane (Merck) and 190g PBS-thimerosal by the method described in the foregoing description #1.

Embodiment #5

Described in embodiment #3, synthetic various sucrose derivatives, the amount of employed parent material is listed in table #5.1.

Table #5.1

Sucrose derivative	Sucrose	Lauroyl chloride	SO 3-pyridine	NMP	Pyridine	Molar ratio
								#	(g)	(g)	(g)	(g)	(g)	L/ sucrose	S/ sucrose
								(lauroyl) 8-sucrose	6.8	35.0	0.0	30	16	8.0	0.0
(sulfuric ester) 1-(lauroyl) 7-sucrose	6.8	30.7	3.2	30	16	7.0	1.0
								(sulfuric ester) 2-(lauroyl) 6-sucrose	6.8	26.3	6.4	30	16	6.0	2.0
(sulfuric ester) 3-(lauroyl) 5-sucrose	6.8	21.9	9.5	30	16	5.0	3.0
								(sulfuric ester) 4-(lauroyl) 4-sucrose	6.8	17.5	12.7	30	16	4.0	4.0
(sulfuric ester) 5-(lauroyl) 3-sucrose	6.8	13.1	15.9	30	16	3.0	5.0
								(sulfuric ester) 6-(lauroyl) 2-sucrose	6.8	8.8	19.1	30	16	2.0	6.0
(sulfuric ester) 7-(lauroyl) 1-sucrose	6.8	4.4	22.3	30	16	1.0	7.0
								(sulfuric ester) 8-sucrose	6.8	0.0	25.4	30	16	0.0	8.0

# molar ratio: L/ sucrose: the dodecanoyl chlorine molal quantity of every mole of sucrose; S/ sucrose: the SO of every mole of sucrose ₃-pyridine molal quantity.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

Prepare the sucrose derivative among the 10g table #5.1 and the preparation of 10g PS (ICI), 40g squalane (Merck) and 190g PBS-thimerosal by the method described in the foregoing description #1.

Measure the effect of the immunne response of the anti-CSFV-E2 of these (several) preparations on one's body pig by method described in the foregoing description #1.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that anti-CSFV in the serum is measured in the virus neutralization tests described in the foregoing description #1.The results are shown in table #5.2.

Measure the antibody titer of 3 weeks of secondary immunity and 12 week backs (strengthening the back) with the ELISA described in the foregoing description #3.The results are shown in table #5.3 and #5.4.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #5.5.

Table #5.2

Group	Vaccine		Strengthen 2-log CSFV-NAT in 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.4	1.2
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	14.9	0.5	31,042
3	CSFV-E2	(sulfuric ester) 2-(lauroyl) 6-sucrose/squalane/PS [40/160/40]	13.7	3.0	13,512
						4	CSFV-E2	(sulfuric ester) 3-(lauroyl) 5-sucrose/squalane/PS [40/40/40]	≥15.3	0.0	≥40,960
5	CSFV-E2	(sulfuric ester) 4-(lauroyl) 4-sucrose/squalane/PS [40/160/40]	15.1	0.4	35,658
						6	CSFV-E2	(sulfuric ester) 5-(lauroyl) 3-sucrose/squalane/PS [40/160/40]	14.2	1.4	19,335
7	CSFV-E2	(sulfuric ester) 6-(lauroyl) 2-sucrose/PS [40/40]	13.5	2.4	11,332

Table #5.3

Group	Vaccine		Strengthen 2-log in the 3 week back serum anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	5.53	1.2	46
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	13.78	1.2	14,067
3	CSFV-E2	(sulfuric ester) 2-(lauroyl) 6-sucrose/squalane/PS [40/160/40]	12.96	1.9	7,968
						4	CSFV-E2	(sulfuric ester) 3-(lauroyl) 5-sucrose/squalane/PS [40/40/40]	13.50	0.7	11,585
5	CSFV-E2	(sulfuric ester) 4-(lauroyl) 4-sucrose/squalane/PS [40/160/40]	15.02	0.4	33,225
						6	CSFV-E2	(sulfuric ester) 5-(lauroyl) 3-sucrose/squalane/PS [40/160/40]	14.76	0.7	27,746
7	CSFV-E2	(sulfuric ester) 6-(lauroyl) 2-sucrose/PS [40/40]	14.39	1.1	21,469

Table #5.4

Group	Vaccine		Strengthen 2-log in the 12 week back serum anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	0.89	0.8	2
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	7.69	1.8	207
3	CSFV-E2	(sulfuric ester) 2-(lauroyl) 6-sucrose/squalane/PS [40/160/40]	5.99	1.7	64
						4	CSFV-E2	(sulfuric ester) 3-(lauroyl) 5-sucrose/squalane/PS [40/40/40]	5.95	1.5	62
5	CSFV-E2	(sulfuric ester) 4-(lauroyl) 4-sucrose/squalane/PS [40/160/40]	8.70	1.5	416
						6	CSFV-E2	(sulfuric ester) 5-(lauroyl) 3-sucrose/squalane/PS [40/160/40]	8.73	0.7	425
7	CSFV-E2	(sulfuric ester) 6-(lauroyl) 2-sucrose/PS [40/40]	8.26	1.3	307

Table #5.5

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	ATM	STDEV	ATM	STDEV
							1	CSFV-E2	No adjuvant	2,216	556	3,468	2,657
2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	8,306	5,943	22,018	28,194
							3	CSFV-E2	(sulfuric ester) 2-(lauroyl) 6-sucrose/squalane/PS [40/160/40]	4,524	3,168	17,856	4,218
4	CSFV-E2	(sulfuric ester) 3-(lauroyl) 5-sucrose/squalane/PS [40/160/40]	8,669	9,617	20,052	10,576
							5	CSFV-E2	(sulfuric ester) 4-(lauroyl) 4-sucrose/squalane/PS [40/160/40]	24,158	13,512	7,218	2,987
6	CSFV-E2	(sulfuric ester) 5-(lauroyl) 3-sucrose/squalane/PS [40/160/40]	1,982	2,264	15,897	11,279
							7	CSFV-E2	(sulfuric ester) 6-(lauroyl) 2-sucrose/squalane/PS [40/160/40]	12,896	15,615	23,204	25,355

Measure the effect of these different preparations antibody response in anti-inactivation influenza virus H1N1 strains A/Swine and H3N2 bacterial strain MRC-11 serum on one's body pig by the ELISA described in the foregoing description #3.The results are shown in table #5.6 and #5.7.

Table #5.6

Group	Vaccine		The antibody titer of the anti-A/Swine ELISA of 2-log in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	A/Swine+M RC-11	No adjuvant	7.69	1.3	207
						2	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	12.02	0.8	4,153
3	A/Swine+M RC-11	(sulfuric ester) 4-(lauroyl) 4-sucrose/squalane/PS [40/160/40]	12.43	0.6	5,518

Table #5.7

Group	Vaccine		The antibody titer of the anti-MRC-11 ELISA of 2-log in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	A/Swine+M RC-11	No adjuvant	10.30	1.1	1,261
						2	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	13.88	1.2	15,076
3	A/Swine+M RC-11	(sulfuric ester) 4-(lauroyl) 4-sucrose/squalane/PS [40/160/40]	15.03	0.8	33,456

Embodiment #6

Described in embodiment #4, synthetic various two sugar derivativess, the amount of parent material is listed in table #6.1.

Table #6.1

Sucrose derivative	Disaccharide		Lauroyl chloride	SO 3-pyridine	NMP	Pyridine	Molar ratio
										(g)	Type	(g)	(g)	(g)	(g)	L/ sugar	S/ sugar
(lauroyl) 7-sucrose	6.8	Sucrose	30.7	0.0	30	16	7.0	0.0
									(sulfuric ester) 0.5-(lauroyl) 7-sucrose	6.8	Sucrose	30.7	1.6	30	16	7.0	0.5
(sulfuric ester) 1-(lauroyl) 7-sucrose	6.8	Sucrose	30.7	3.2	30	16	7.0	1.0
									(lauroyl) 7-maltose	7.3	Maltose	30.7	0.0	30	16	8.0	0.0
(sulfuric ester) 0.5-(lauroyl) 7-maltose	7.3	Maltose	30.7	3.2	30	16	8.0	0.5
									(sulfuric ester) 1-(lauroyl) 7-maltose	7.3	Maltose	30.7	6.4	30	16	8.0	1.0
(lauroyl) 7-lactose	7.3	Lactose	30.7	0.0	30	16	8.0	0.0
									(sulfuric ester) 0.5-(lauroyl) 7-lactose	7.3	Lactose	30.7	3.2	30	16	8.0	0.5
(sulfuric ester) 1-(lauroyl) 7-lactose	7.3	Lactose	30.7	6.4	30	16	8.0	1.0

# molar ratio: L/ sugar: the dodecanoyl chlorine molal quantity of every mole of disaccharide; S/ sugar: the SO of every mole of disaccharide ₃-pyridine molal quantity.

Maltose=maltose monohydrate (Merck), lactose=alpha-lactose monohydrate (Acros).

By the TLC method described in the embodiment #1 product that obtains is analyzed.

Press the sucrose derivatives different among the method preparation table #6.1 described in the foregoing description #1 and the preparation of PS (ICI), squalane (Merck) and PBS-thimerosal.

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that anti-CSFV in the serum is measured in the virus neutralization tests described in the foregoing description #1.The results are shown in table #6.2.

Measure the antibody titer of 3 weeks of secondary immunity and 12 week backs (strengthening the back) with the ELISA described in the foregoing description #3.The results are shown in table #6.3 and #6.4.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #6.5.

Table #6.2

Group	Vaccine		Strengthen 2-log CSFV-NAT in 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.4	1.2	11
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	14.9	0.5	31,042
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-maltose/squalane/PS [40/160/40]	13.2	1.7	9,176
						4	CSFV-E2	(sulfuric ester) 1-(myristoyl) 7-lactose-IV/ squalane/PS [40/40/40]	≥15.3	0.0	≥40,960

Table #6.3

Group	Vaccine		Strengthen 2-log in the 3 week back serum anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	5.53	1.2	46
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	13.78	1.2	14,067
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-maltose/squalane/PS [40/160/40]	13.08	1.0	8,659
						4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-lactose-IV/ squalane/PS [40/160/40]	14.88	0.8	30,153

Table #6.4

Group	Vaccine		Strengthen 2-log in the 12 week back serum anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	0.89	0.8	2
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	7.69	1.8	207
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-maltose/squalane/PS [40/160/40]	6.96	1.1	124
						4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-lactose-IV/ squalane/PS [40/160/40]	8.48	1.1	357

Table #6.5

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	GMT	STDEV	GMT	STDEV
							1	CSFV-E2	No adjuvant	2,216	556	3,468	2,657
2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	8,306	5,943	22,018	28,194
							3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-maltose/squalane/PS [40/160/40]	2,602	1,508	18,130	12,111
4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-lactose-IV/ squalane/PS [40/160/40]	6,415	7,392	27,595	24,289

Measure the effect of these different preparations antibody response in anti-inactivation influenza virus H1N1 strains A/Swine and H3N2 bacterial strain MRC-11 serum on one's body pig by the ELISA described in the foregoing description #3.The results are shown in table #6.6 and #6.7.

Table #6.6

Group	Vaccine		The antibody titer of the anti-A/Swine ELISA of 2-log in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	A/Swine+M RC-11	No adjuvant	7.69	1.3	207
						2	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	12.02	0.8	4,153
3	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-maltose/squalane/PS [40/160/40]	10.80	1.0	1,783
						4	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-lactose-IV/ squalane/PS [40/160/40]	11.34	1.1	2,592

Table #6.7

Group	Vaccine		The antibody titer of the anti-MRC-11 ELISA of 2-log in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	A/Swine+M RC-11	No adjuvant	10.30	1.1	1,261
						2	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	13.88	1.2	15,076
3	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-maltose/squalane/PS [40/160/40]	12.93	0.9	7,804
						4	A/Swine+M RC-11	(sulfuric ester) 1-(lauroyl) 7-lactose-IV/ squalane/PS [40/160/40]	13.29	1.2	10,016

Embodiment #7

By making sucrose fatty acid ester L195 (Mitsubishi-Kagaku food company, Tokyo, Japan) and SO ₃-pyridine synthesizes various two sugar derivativess about 6 hours of 60 ℃ of contacts.The amount of parent material is listed in table #7.1.

Table #7.1

Sucrose derivative	Sucrose fatty acid ester L195	SO 3-pyridine	NMP	Pyridine	Molar ratio
								(g)	(g)	(g)	(g)	L/ sugar *	S/ sugar
L195	27.8	0	20	0	5.7	0.0
							(sulfuric ester) 1-L195	27.8	3.2	20	0	5.7	1.0
(sulfuric ester) 2-L195	27.8	6.4	20	0	5.7	2.0
							(sulfuric ester) 2.3-L195	27.8	7.3	20	0	5.7	3.0

# molar ratio: the dodecanoyl chlorine molal quantity of L/ sugar=every mole of L195; The SO of S/ sugar=every mole of L195 ₃-pyridine molal quantity.

^*Supplier with reference to L195.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

The preparation for preparing sucrose derivative, 10g PS (ICI), 40g squalane (Merck) and 190g PBS-thimerosal among the 10g table #7.1 by the method described in the foregoing description #1.

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that anti-CSFV in the serum is measured in the virus neutralization tests described in the foregoing description #1.The results are shown in table #7.2.

Measure the antibody titer of 3 weeks of secondary immunity and 12 week backs (strengthening the back) with the ELISA described in the foregoing description #3.The results are shown in table #7.3 and #7.4.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #7.5.

Table #7.2

Group	Vaccine		Secondary inoculation 2-log CSFV-NAT after 3 weeks
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.4	1.2	11
						2	CSFV-E2	L195/ squalane/PS [40/160/40]
3	CSFV-E2	(sulfuric ester) 1-L195/ squalane/PS [40/160/40]	14.5	1.1	23,525
						4	CSFV-E2	(sulfuric ester) 2-L195/ squalane/PS [40/40/40]	13.8	1.3	13,834
5	CSFV-E2	(sulfuric ester) 2.3-L195/ squalane/PS [40/40/40]	14.6	0.9	25,631

Table #7.3

Group	Vaccine		Secondary inoculation 3 week back 2-log are anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	5.53	1.2	46
						2	CSFV-E2	L195/ squalane/PS [40/160/40]	12.20	1.2	4,705
3	CSFV-E2	(sulfuric ester) 1-L195/ squalane/PS [40/160/40]	13.79	1.4	14,165
						4	CSFV-E2	(sulfuric ester) 2-L195/ squalane/PS [40/40/40]	14.18	1.6	18,561
5	CSFV-E2	(sulfuric ester) 2.3-L195/ squalane/PS [40/40/40]	14.22	1.0	19,083

Table #7.4

Group	Vaccine		Secondary inoculation 12 week back 2-log are anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDE V	Antilogarithm
1	CSFV-E2	No adjuvant	0.89	0.8	2
						2	CSFV-E2	L195/ squalane/PS [40/160/40]	5.89	0.6	59
3	CSFV-E2	(sulfuric ester) 1-L195/ squalane/PS [40/160/40]	7.13	0.9	140
						4	CSFV-E2	(sulfuric ester) 2-L195/ squalane/PS [40/40/40]	7.37	1.7	165
5	CSFV-E2	(sulfuric ester) 2.3-L195/ squalane/PS [40/40/40]	8.41	1.0	340

Table #7.5

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	AMT	STDEV	AMT	STDEV
							1	CSFV-E2	No adjuvant	2,216	556	3,468	2,657
2	CSFV-E2	L195/ squalane/PS [40/160/40]	7,157	8,943	18,807	20,879
							3	CSFV-E2	(sulfuric ester) 1-L195/ squalane/PS [40/160/40]	3,104	2,062	18,710	26,432
4	CSFV-E2	(sulfuric ester) 2-L195/ squalane/PS [40/40/40]	8,310	9,680	29,835	36,351
							5	CSFV-E2	(sulfuric ester) 2.3-L195/ squalane/PS [40/40/40]	513	932	6,515	5,337

Measure the effect of these different preparations antibody response in anti-inactivation influenza virus H1N1 strains A/Swine and H3N2 bacterial strain MRC-11 serum on one's body pig by the ELISA described in the foregoing description #3.The results are shown in table #7.6 and #7.7.

Table #7.6

Group	Vaccine		The antibody titer of the anti-A/Swine ELISA of secondary inoculation 3 week back 2-log
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	A/Swine+MRC-11	No adjuvant	7.69	1.3	207
						2	A/Swine+MRC-11	L195/ squalane/PS [40/160/40]	12.76	1.3	6,937
3	A/Swine+MRC-11	(sulfuric ester) 1-L195/ squalane/PS [40/160/40]	12.78	1.0	7,033
						4	A/Swine+MRC-11	(sulfuric ester) 2-L195/ squalane/PS [40/40/40]	12.69	0.5	6,608
5	A/Swine+MRC-11	(sulfuric ester) 2.3-L195/ squalane/PS [40/40/40]	12.47	1.1	5,673

Table #7.7

Group	Vaccine		The antibody titer of the anti-MRC-11 ELISA of secondary inoculation 3 week back 2-log
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	A/Swine+MRC-11	No adjuvant	10.30	1.1	1,261
						2	A/Swine+MRC-11	L195/ squalane/PS [40/160/40]	14.76	1.4	27,746
3	A/Swine+MRC-11	(sulfuric ester) 1-L195/ squalane/PS [40/160/40]	14.54	1.4	23,822
						4	A/Swine+MRC-11	(sulfuric ester) 2-L195/ squalane/PS [40/40/40]	14.39	0.7	21,469
5	A/Swine+MRC-11	(sulfuric ester) 2.3-L195/ squalane/PS [40/40/40]	14.59	0.7	24,662

Embodiment #8

The preparation for preparing 40g L195 (Mitsubishi-Kagaku food company, Tokyo, Japan), 10g PS (ICI) and 200gPBS-thimerosal by the method described in the foregoing description #1.

Prepare (sulfuric ester) 1-(dodecanoyl) the 7-sucrose of 10g embodiment #5 and the preparation of 10g PS (ICI), 40g L195 (Merck) and 190g PBS-thimerosal by the method described in the foregoing description #1.

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that anti-CSFV in the serum is measured in the virus neutralization tests described in the foregoing description #1.The results are shown in table #8.2.

Measure the antibody titer of 3 weeks of secondary immunity and 12 week backs (strengthening the back) with the ELISA described in the foregoing description #3.The results are shown in table #8.3 and #8.4.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #8.5.

Table #8.2

Group	Vaccine		Secondary inoculation 2-log CSFV-NAT after 3 weeks
							Antigen	Adjuvant	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.4	1.2	11
						2	CSFV-E2	L195/ PS [160/40]	8.7	1.5	403
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/L195 (embodiment #5)/PS [40/160/40]	11.0	3.3	2,104

Table #8.3

Group	Vaccine		Secondary inoculation 3 week back 2-log are anti--antibody titer of E2 ELISA
							Antigen	Adjuvant	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	5.53	1.2	46
						2	CSFV-E2	L195/ PS [160/40]	10.32	1.0	1,278
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/L195 (embodiment #5)/PS [40/160/40]	15.21	0.7	37,902

Table #8.4

Group	Vaccine		Secondary inoculation 12 week back 2-log are anti--antibody titer of E2 ELISA
							Antigen	Adjuvant	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	0.89	0.8	2
						2	CSFV-E2	L195/ PS [160/40]	4.84	0.9	29
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/L195 (embodiment #5)/PS [40/160/40]	8.41	1.0	340

Table #8.5

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant	AMT	STDEV	AMT	STDEV
							1	CSFV-E2	No adjuvant	2,216	556	3,468	2,657
2	CSFV-E2	L195/ PS [160/40]	8,306	5,943	22,018	28,194
							3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/L195 (embodiment #5)/PS [40/160/40]	3,801	4,775	4,605	2,490

Embodiment #9

By making 0.02 mole of sucrose contact about 6 hours at 60 ℃, synthesize (oleoyl) 8-sucrose with 0.15 mole of oleoyl chloride (Merck).This sucrose derivative carries out extracting with normal hexane.Method of evaporating by the increase temperature described in the foregoing description #2, minimizing pressure is removed normal hexane.By the TLC method described in the embodiment #1 product that obtains is analyzed.

3 kinds of different sucrose octaoleate ester emulsions have been prepared.By the amount shown in the table #9.1 (oleoyl) 8-sucrose, squalane, PS and PBS-thimerosal are mixed, and carry out emulsifying by method described in the foregoing description #1.In addition, mix, prepare squalane/PS emulsion of no sucrose octaoleate by the amount of showing squalane, PS and the PBS-thimerosal shown in the #9.1.

Table #9.1

Emulsion	(oleic acid) 8-sucrose (g)	Squalane (g)	Multi-sorbitol ester (g)	PBS-thimerosal (g)
					Squalane/PS [160/40]	0	40	10	200
(oleic acid) 8-sucrose/PS [160/40]	40	0	10	200
					(oleic acid) 8-sucrose/squalane/PS [40/160/40]	10	40	10	1190
(oleic acid) 8-sucrose/squalane/multi-sorbitol ester [80/160/40]	20	20	10	200

The method described in the foregoing description #1 of pressing is measured the effect of emulsion antagonism CSFV-E2 virucidin reaction among the table #9.1.SL-CD/ squalane immersion (Fort Dodge AnimalHealth Holland, Weesp, Holland) is included in interior with for referencial use.The results are shown in table #9.2.

Table #9.2

Group	Vaccine		2-log CSFV-NAT in enhance immunity 3 all backs serum
							Antigen	Adjuvant	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.64	0.00	13
						2	CSFV-E2	Squalane/PS [160/40]	5.36	1.48	41
3	CSFV-E2	(oleic acid) 8-sucrose/PS [160/40]	4.88	1.14	29
						4	CSFV-E2	(oleic acid) 8-sucrose/squalane/PS [40/160/40]	6.27	1.05	77
5	CSFV-E2	(oleic acid) 8-sucrose/squalane/multi-sorbitol ester [80/160/40]	5.68	2.00	51
						6	CSFV-E2	SL-CD/ squalane immersion (Fort Dodge Animal Health)	10.44	0.45	1,393

Table #9.1 is listed in the preparation of different adjuvants.The dosage of CSFV-E2 is 32 μ g/ animals.

Embodiment #10

With inactivation influenza virus bacterial strain MRC-11 and A/Swine and 10 commercially available, that contain 4.0 and 4.4 μ g HA/ dosage ^8.3TCID ₅₀Pseudorabies/the influenza virus vaccine of the inactivation pseudorabies virus of/dosage (SuvaxynO/W of Fort Dodge Animal Health Holland; Weesp, Holland) 100/0,33/66,20/80 and 10/90 mix by volume with (sulfuric ester)-(dodecanoyl) 7-sucrose/squalane/PS adjuvant prescription of embodiment #1.With each twice of group pig immunity and press (vaccine, 1994,12,653-660 page or leaf) described virus neutralization tests method such as Hilgers and measure the antibody response of anti-pseudorabies virus.The results are shown in table #10.1.Press the antibody response that the ELISA described in the embodiment #3 measures resisiting influenza virus strains A/Swine and MRC-11.The result lists in table #10.2 and #10.3 respectively.

Table #10.1

Group	Vaccine is formed (volume %)		The NAT of 2-log PRV in enhance immunity 3 all backs serum
							Syvaxyn O/W	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	GMT	STDEV	Antilogarithm
1	100	0	4.07	2.0	17
						2	33	66	5.54	1.8	47
3	20	80	1.95	2.1	4
						4	10	90	0.80	1.1	1

Table #10.2

Group	Vaccine is formed (volume %)		2-log A/Swine ELISA antibody titer in enhance immunity 3 all backs serum
							Syvaxyn O/W	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	GMT	STDEV	Antilogarithm
1	100	0	10.44	0.8	1,389
						2	33	66	12.44	0.7	5,557
3	20	80	11.43	1.2	2,759
						4	10	90	11.51	1.1	2,916

Table #10.3

Group	Vaccine is formed (percent by volume)		2-log MRC-11 ELISA antibody titer in enhance immunity 3 all backs serum
							Syvaxyn O/W	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	GMT	STDEV	Antilogarithm
1	100	0	12.93	1.1	7,804
						2	33	66	15.01	0.8	32,996
3	20	80	14.73	0.8	27,175
						4	10	90	14.74	1.2	27,364

Embodiment #11

Press described in the embodiment #1 synthesis of sucrose derivant.The amount of used parent material is listed in table #11.1.

Table #11.1

Sucrose derivative	Sucrose	Acyl chlorides		SO 3-pyridine	NMP	Pyridine	Molar ratio
										(g)	(g)	(type)	(g)	(g)	(g)	L/ sucrose	S/ sucrose
									(sulfuric ester) 1-(lauroyl) 7-sucrose	17.1	76.7	Lauroyl chloride	8	74	40	7.0	1.0

# molar ratio: L/ sucrose: the acyl chlorides molal quantity of every mole of sucrose; S/ sucrose: the SO of every mole of sucrose ₃-pyridine molal quantity.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

Press the sucrose derivative among the method preparation table #10.1 described in the foregoing description #1 and the preparation of PS (ICI), squalane (Merck) and PBS-thimerosal.

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that anti-CSFV in the serum is measured in the virus neutralization tests described in the foregoing description #1.The results are shown in table #11.2.

Measure antibody titer with the ELISA described in the foregoing description #3.The results are shown in table #11.3.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #11.4.

Table #11.2

Group	Vaccine		Strengthen 2-log CSFV-NAT in 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.7	0.3	13
						3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/PS [40/40]	7.4	3.0	675
4	CSFV-E2	Squalane/PS [160/40]	5.8	1.7	89
						5	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40]	12.0	1.8	7,424
6	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40] is separated injection with antigen	10.2	3.0	3,787

Table #11.3

Group	Vaccine		Strengthen 2-log in the 3 week back serum anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	2.5	0.7	6
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/PS [40/40]	6.3	1.8	80
3	CSFV-E2	Squalane/PS [160/40]	3.1	2.4	8.7
						4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40]	9.1	1.4	555
5	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40] is separated injection with antigen	7.9	0.9	241

Table #11.4

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	GMT	STDEV	GMT	STDEV
							1	CSFV-E2	No adjuvant	184	196	325	543
2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/PS [40/40]	2,257	1,389	7,601	7,186
							3	CSFV-E2	Squalane/PS [160/40]	1,298	1,324	516	789
4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40]	1,654	760	37,204	28,026
							5	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40] is separated injection with antigen	5,195	5,134	14,210	12,003

Embodiment #12

Press described in the embodiment #1 synthetic several sucrose derivatives.Sucrose is contacted with lauroyl chloride (Merck), decanoyl chloride (Merck), stearoyl chlorine (Merck) or hexadecanoyl chloride (Merck), and and SO ₃The contact of-pyridine.The amount of used parent material is listed in table #12.1.

Table #12.1

Sucrose derivative	Sucrose	Acyl chlorides		SO 3-pyridine	NMP	Pyridine	Molar ratio
										(g)	(g)	(type)	(g)	(g)	(g)	L/ sucrose	S/ sucrose
									(sulfuric ester) 1-(lauroyl) 7-sucrose	17.1	76.7	Lauroyl chloride	8	74	40	7.0	1.0
(sulfuric ester) 1-(caprinoyl) 7-sucrose	17.1	66.8	Decanoyl chloride	8	74	40	7.0	1.0
									(sulfuric ester) 1-(decoyl) 7-sucrose	17.1	56.9	Caprylyl chloride	8	74	40	7.0	1.0
(sulfuric ester) 1-(hexanoyl) 7-sucrose	17.1	47.1	Caproyl chloride	8	74	40	7.0	1.0

# molar ratio: L/ sucrose: the acyl chlorides molal quantity of every mole of sucrose; S/ sucrose: the SO of every mole of sucrose ₃-pyridine molal quantity.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

Press the sucrose derivative among the method preparation table #12.1 described in the foregoing description #1 and the preparation of PS (ICI), squalane (Merck) and PBS-thimerosal.

Measure the effect of the anti-CSFV-E2 immunne response of these preparations on one's body pig by method described in the foregoing description #1.The results are shown in table #12.2.

Measure antibody titer with the ELISA described in the foregoing description #3.The results are shown in table #12.3.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #12.4.

Table #12.2

Group	Vaccine		2-log CSFV-NAT in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.7	0.3	13
						3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40]	12.0	1.8	7,424
4	CSFV-E2	(sulfuric ester) 1-(caprinoyl) 7-sucrose/squalane/PS [40/1600/40]	14.1	1.6	25,088
						5	CSFV-E2	(sulfuric ester) 1-(decoyl) 7-sucrose/squalane/PS [40/1600/40]	13.4	1.9	17,152
6	CSFV-E2	(sulfuric ester) 1-(hexanoyl) 7-sucrose/squalane/PS [40/1600/40]	9.7	2.3	2,280

Table #12.3

Group	Vaccine		In the enhance immunity 3 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	2.5	0.7	6
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40]	9.1	1.4	555
3	CSFV-E2	(sulfuric ester) 1-(caprinoyl) 7-sucrose/squalane/PS [40/1600/40]	11.0	2.0	2,062
						4	CSFV-E2	(sulfuric ester) 1-(decoyl) 7-sucrose/squalane/PS [40/1600/40]	10.1	1.2	1,113
5	CSFV-E2	(sulfuric ester) 1-(hexanoyl) 7-sucrose/squalane/PS [40/1600/40]	7.9	1.3	243

Table #12.4

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	GMT	STDEV	GMT	STDEV
							1	CSFV-E2	No adjuvant	184	196	325	543
2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/1600/40]	1,654	760	37,204	28,026
							3	CSFV-E2	(sulfuric ester) 1-(caprinoyl) 7-sucrose/squalane/PS [40/1600/40]	8,627	7,816	52,791	24,632
4	CSFV-E2	(sulfuric ester) 1-(decoyl) 7-sucrose/squalane/PS [40/1600/40]	2,995	1,899	33,172	27,272
							5	CSFV-E2	(sulfuric ester) 1-(hexanoyl) 7-sucrose/squalane/PS [40/1600/40]	1,310	547	34,809	31,555

Embodiment #13

Prepare sucrose ester L195 (Mitsubishi-Kagaku food company by the method described in the foregoing description #, Tokyo, Japan), (oleoyl) 8-sucrose, the dimethyl two-octadecyl bromination ammonium (DDA among PS (Merck), squalane (Merck), the embodiment #9; Eastman Kodak company, Rochester, NY), carbopol 934PH (BFGoodrich, Cleveland, preparation OH).The amount of used parent material is listed in table #13.1.

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.The results are shown in table #13.2.

Measure antibody titer with the ELISA described in the foregoing description #3.The results are shown in table #13.3.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #13.4.

Table #13.1

Emulsion	Form
Squalane/PS [160/40]	40g squalane+10g PS+190g PBS-thimerosal
		L195/ squalane/PS [40/160/40]	10g sucrose ester L195+40g squalane+10g PS+190g PBS-thimerosal
L195/ (oleoyl) 8-sucrose/PS [40/160/40]	10g sucrose ester L195+40g (oleoyl) 8-sucrose+10g PS+190g PBS-thimerosal
		L195/DDA/ squalane/PS [40/40/160/40]	10g sucrose ester L195+10g DDA+40g squalane+10g PS+180g PBS-thimerosal
L195/ carbopol/squalane/PS [40/4/160/40]	10g sucrose ester L195+1g carbopol+40g squalane+10g PS+189g PBS-thimerosal

Table #13.2

Group	Vaccine		2-log CSFV-NAT in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.7	0.3	13
						2	CSFV-E2	Squalane/PS [160/40]	5.8	1.7	89
3	CSFV-E2	L195/ squalane/PS [40/160/40]	13.0	2.1	18,176
						4	CSFV-E2	L195/ (oleoyl) 8-sucrose/PS [40/160/40]	8.1	0.9	312
5	CSFV-E2	L195/DDA/ squalane/PS [40/40/160/40]	11.0	1.7	3,488
						6	CSFV-E2	L195/ carbopol/squalane/PS [40/4/160/40]	12.8	0.6	7,424

Table #13.3

Group			In the enhance immunity 3 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	2.5	0.7	6
						2	CSFV-E2	Squalane/PS [160/40]	3.1	2.4	9
3	CSFV-E2	L195/ squalane/PS [40/160/40]	9.0	1.4	495
						4	CSFV-E2	L195/ (oleoyl) 8-sucrose/PS [40/160/40]	6.4	0.6	84
5	CSFV-E2	L195/DDA/ squalane/PS [40/40/160/40]	9.3	1.3	609
						6	CSFV-E2	L195/ carbopol/squalane/PS [40/4/160/40]	9.0	0.7	510

Table #13.4

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	AMT	STDE V	AMT	STDE V
							1	CSFV-E2	No adjuvant	184	196	325	543
2	CSFV-E2	Squalane/PS [160/40]	1,298	1,324	516	789
							3	CSFV-E2	L195/ squalane/PS [40/160/40]	3,363	2,077	15,626	9,599
4	CSFV-E2	L195/ (oleoyl) 8-sucrose/PS [40/160/40]	NT		1,629	1,226
							5	CSFV-E2	L195/DDA/ squalane/PS [40/40/160/40]	17,145	20,804	34,536	30,990
6	CSFV-E2	L195/ carbopol/squalane/PS [40/4/160/40]	NT		46,345	31,655

NT=does not detect

Embodiment #14

Press described in the embodiment #1 synthetic mannose derivative.The amount of used parent material is listed in table #14.1.

Table #14.1

Sucrose derivative	Mannose	Acyl chlorides		SO 3-pyridine	NMP	Pyridine	Molar ratio
										(g)	(g)	(type)	(g)	(g)	(g)	L/ maltose	S/ maltose
									(sulfuric ester) 1-(lauroyl) 4-mannose	9.0	43.8	Lauroyl chloride	8.0	74	40	4.0	1.0

# molar ratio: L/ mannose: the acyl chlorides molal quantity of every mole of mannose; S/ mannose: the SO of every mole of mannose ₃-pyridine molal quantity.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

Prepare the mannose derivative among the 10g table #14.1 and the preparation of 10g PS (ICI), 40g squalane (Merck) and 190g PBS-thimerosal by the method described in the foregoing description #1.

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.The results are shown in table #14.2.

Measure antibody titer with the ELISA described in the foregoing description #3.The results are shown in table #14.3.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #14.4.

Table #14.2

Group	Vaccine		2-log CSFV-NAT in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.7	0.3	13
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 4-mannose/squalane/PS [40/160/40]	11.8	1.1	4,352

Table #14.3

Group	Vaccine		In the enhance immunity 3 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	2.5	0.7	6
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 4-mannose/squalane/PS [40/160/40]	8.7	0.9	411

Table #14.4

Group	Vaccine		Stimulation index			Stimulation index
										After inoculating for 3 weeks first			Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	AMT	STDEV	AMT	STDEV
							1	CSFV-E2	No adjuvant	184	196	325	543
2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 4-mannose/squalane/PS [40/160/40]	4,292	2,503	30,146	26,889

Embodiment #15

Press described in the embodiment #1 synthetic (sulfuric ester) 1-(lauroyl) 2-glycerol.4.6g anhydrous glycerol (Merck) is dissolved in anhydrous N-methyl-pyrrolidone (Merck) and the anhydrous pyridine (Merck).Add the lauroyl chloride (Merck) of 21.9g and reactant mixture was bathed 6 hours in 60 ℃ of temperature.Add 8.0g SO ₃-pyridine (Merck) is also bathed reactant mixture 18 hours in the room temperature temperature.In 4 ℃ of maintenances 24 hours, make its formation biphase this reactant mixture.Phase in the collection, and to increase temperature (＜60 ℃), to reduce pressure (＜10mbar) method is evaporated, and in 4 ℃ of condensations, till the residual loss in weight was less than 0.1g/30 minute, to remove N-N-methyl 2-pyrrolidone N-and pyridine.

By the TLC method described in the embodiment #1 (sulfuric ester) 1-(lauroyl) 2-glycerol that obtains is analyzed.

The preparation for preparing 10g glycerol derivatives, 10g PS (ICI), 40g squalane (Merck) and 190g PBS-thimerosal by the method described in the foregoing description #1.

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.The results are shown in table #15.1.

Measure antibody titer with the ELISA described in the foregoing description #3.The results are shown in table #15.2.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #15.3.

Table #15.1

Group	Vaccine		2-log CSFV-NAT in enhance immunity 3 all backs serum
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	3.7	0.3	13
						3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 2-glycerol/squalane/PS [40/160/40]	4.8	2.0	51

Table #15.2

Group	Vaccine		In the enhance immunity 3 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	2.5	0.7	6
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 2-glycerol/squalane/PS [40/160/40]	3.9	2.0	15

Table #15.3

Group	Vaccine		Stimulation index		Stimulation index
										After inoculating for 3 weeks first		Secondary inoculation is after 3 weeks
	Antigen	Adjuvant prescription	AMT	STDEV	AMT	STDEV
							1	CSFV-E2	No adjuvant	184	196	325	543
2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 2-glycerol/squalane/PS [40/160/40]	NT		2,842	853

NT=does not detect

Embodiment #16

The preparation for preparing 1.3g sucrose ester L195 (Mitsubishi-Kagaku food company, Tokyo, Japan), 1.3g PS (Merck), 10.8g squalane (Merck), 237.7g PBS-thimerosal by the method described in the foregoing description #1.

The preparation for preparing (sulfuric ester) 1-(lauroyl) 7-sucrose, 1.3g PS (Merck), 10.8g angle Squalene (Merck) and 238.1g PBS-thimerosal among the 1.3g embodiment #12 by the method described in the foregoing description #1.

Measured the ELISA antibody response effect of these several preparations in anti-inactivation human influenza virus strains A/Panama, A/New CAledonia and B/Yamanashi serum on one's body pig.For this reason, with the influenza virus vaccine INFLUVAC in the commercially available Solvay of potion (0.5ml) pharmaceutical factory (Weesp, Holland) ^TMMix with the arbitrary adjuvant prescription of 1ml, and 5 groups of pigs are carried out immunity.First immunisation is measured antibody response with the ELISA described in the embodiment #3 after three weeks.By measuring with the Solvay pharmaceutical factory INFLUVAC that does not have adjuvant ^TMAntibody response behind the secondary immunity is measured the inducing action of immunological memory.

The result of anti-A/Panama, A/New CAledonia and B/Yamanashi antibody titer lists in table #16.1, #16.2 and #16.3 respectively after the first immunisation.The secondary immunity of no adjuvant is after one week, and the result of anti-A/Panama, A/New CAledonia and B/Yamanashi antibody titer lists in table #16.4, #16.5 and #16.6 respectively.The secondary immunity of no adjuvant is after three weeks, and the result of anti-A/Panama, A/New CAledonia and B/Yamanashi antibody titer lists in table #16.7, #16.8 and #16.9 respectively.

Table #16.1

Group	Vaccine		In the first immunisation 3 week back serum 2-log anti--antibody titer of A/Panama ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	4.4	0.8	22
						2	INFLUVAC	L195/ angle Squalene/PS [5/43/5]	8.3	0.8	322
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/angle Squalene/PS [5/43/5]	7.9	0.8	241

Table #16.2

Group	Vaccine		In the first immunisation 3 week back serum 2-log anti--antibody titer of A/New Caledonia ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	4.3	0.8	19
						2	INFLUVAC	L195/ angle Squalene/PS [5/43/5]	8.0	0.5	259
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/angle Squalene/PS [5/43/5]	8.0	1.0	247

Table #16.3

Group	Vaccine		In the first immunisation 3 week back serum 2-log anti--antibody titer of B/Yamanashi ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	4.9	0.9	29
						2	INFLUVAC	L195/ angle Squalene/PS [5/43/5]	9.0	0.5	503
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/angle Squalene/PS [5/43/5]	8.7	1.0	411

Table #16.4

Group	Vaccine		In the secondary immunity 3 week back serum 2-log anti--antibody titer of A/Panama ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	5.8	1.4	56
						2	INFLUVAC	L195/ angle Squalene/PS [5/43/5]	10.6	1.6	1,513
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [5/43/5]	10.1	1.1	1,061

Table #16.5

Group	Vaccine		In the secondary immunity 3 week back serum 2-log anti--antibody titer of A/New Caledonia ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	5.8	1.3	57
						2	INFLUVAC	L195/ Squalene/PS [5/43/5]	10.9	1.0	1,898
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [5/43/5]	10.4	1.2	1,313

Table #16.6

Group	Vaccine		In the secondary immunity 3 week back serum 2-log anti--antibody titer of B/Yamanashi ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	6.3	1.3	81
						2	INFLUVAC	L195/ Squalene/PS [5/43/5]	11.1	1.0	2,260
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [5/43/5]	11.9	1	1,868

Table #16.7

Group	Vaccine		In the secondary immunity 3 week back serum 2-log anti--antibody titer of A/Panama ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	5.8	1.8	54
						2	INFLUVAC	L195/ Squalene/PS [5/43/5]	9.2	1.6	573
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [5/43/5]	8.6	1.0	383

Table #16.8

Group	Vaccine		In the secondary immunity 3 week back serum 2-log anti--antibody titer of A/New Caledonia ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	6.1	2.0	70
						2	INFLUVAC	L195/ Squalene/PS [5/43/5]	9.0	0.9	496
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [5/43/5]	8.7	1.2	419

Table #16.9

Group	Vaccine		In the secondary immunity 3 week back serum 2-log anti--antibody titer of B/Yamanashi ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	INFLUVAC	No adjuvant	6.1	1.6	68
						2	INFLUVAC	L195/ Squalene/PS [5/43/5]	9.3	1.1	613
3	INFLUVAC	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [5/43/5]	8.9	0.9	472

Embodiment #17

Press method described in the embodiment #1, by making 205.2g sucrose and 198g lauroyl chloride and 98g SO ₃The contact of-pyridine, synthetic (sulfuric ester) 1-(lauroyl) 7-sucrose.This sucrose ester carries out extracting by method described in the foregoing description #2 with normal hexane.

Press method described in the embodiment #1, by making 23.9g sucrose and 67.5g lauroyl chloride and 45.6g SO ₃The contact of-pyridine, synthetic (sulfuric ester) 4-(lauroyl) 4-sucrose.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

With squalane (Merck), Squalene (Merck), hexadecane (Acros, Geel, Belgium), triolein (Sigma, St.Louis, MI), Markol (Esso), perfluoro-octyl bromide (perfluorooctylbromide) (Acros) or silicone oil as oil, PS (Merck), Spheron MD 30/70 20 (Baker), L1695 (Mitsubishi-Kagaku), Triton X-100 (Sigma), saponin (Fluka, Zwijndrecht, Holland) or (sulfuric ester) 4-(lauroyl) 4-sucrose as emulsifying agent and PBS-thimerosal or the WFI (water for injection of ID-Lelystad, Lelystad, Holland) as water, by amount preparation (sulfuric ester) 1-(lauroyl) 7-sucrose adjuvant prescription shown in the following table #17.1.

These preparations carry out emulsifying by method described in the foregoing description #1.

Table #17.1

Emulsion	Form
						Sucrose ester	Oil	Emulsifying agent/stabilizing agent	Water
(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g squalane	The 10g PS	190g PBS-thimerosal
					(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g Squalene	The 10g PS	190g PBS-thimerosal
(sulfuric ester) 1-(lauroyl) 7-sucrose/hexadecane/PS [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g hexadecane	The 10g PS	190g PBS-thimerosal
					(sulfuric ester) 1-(lauroyl) 7-sucrose/hexadecane/PS [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g triolein	The 10g PS	190g PBS-thimerosal
(sulfuric ester) 1-(lauroyl) 7-sucrose/Markol/ PS [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	40g Markol 52	The 10g PS	190g PBS-thimerosal
					(sulfuric ester) 1-(lauroyl) 7-sucrose/silicone oil/PS [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	40g silicone oil	The 10g PS	190g PBS-thimerosal
(sulfuric ester) 1-(lauroyl) 7-sucrose/fluorbron/ PS [40/160/40]	5g (sulfuric ester) 1-(lauroyl) 7-sucrose	20g perfluorooct ylbromide	The 5g PS	95g PBS-thimerosal
					(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/L1695[40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g Squalene	10g L1695	190g PBS-thimerosal
(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/(sulfuric ester) 4-(lauroyl) 4-sucrose [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g Squalene	10g (sulfuric ester) 4-(lauroyl) 4-sucrose	190g PBS-thimerosal
					(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/Spheron MD 30/70 20[40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g Squalene	10g multi-sorbitol ester 20	190g PBS-thimerosal
(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/Triton X-100[40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g Squalene	10g Triton X-100	190g PBS-thimerosal
					(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/saponin [40/160/40]	10g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 40g Squalene	The 10g saponin	190g PBS-thimerosal
(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [80/3200/80]	20g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 80g squalane	The 20g PS	130g PBS-thimerosal
					(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [120/480/120]	30g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 120g squalane	The 30g PS	70g PBS-thimerosal
(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [160/640/120]	40g (sulfuric ester) 1-(lauroyl) 7-sucrose	The 160g squalane	The 40g PS	10g WFI

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.1 group and 2 groups respectively has 5 pigs, and 3 groups and 10 groups respectively have 4 pigs.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that the ELISA described in the foregoing description #3 measures anti-CSFV in the serum.The results are shown in table #17.2.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #17.3.

Table #17.2

Group	Vaccine		In the enhance immunity 1 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	6.4	2.0	86
						2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	15.9	0.9	60,720
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [80/320/80]	16.2	0.8	72,977
						4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [40/160/40]	14.2	0.8	18,940
5	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/L1695[40/160/40]	14.7	1.1	26,489
						6	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/(sulfuric ester) 4-(lauroyl) 4-sucrose [40/160/40]	12.3	1.1	4,897
7	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/(sulfuric ester) 4-(lauroyl) 4-sucrose [80/320/80]	13.4	1.6	10,925
						8	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Markol/ PS [40/160/40]	15.6	1.2	49,123
9	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/silicone oil/PS [40/160/40]	13.5	1.5	11,281
						10	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/perfluoro-octyl bromide/PS [40/160/40]	13.4	1.2	11,059

Table #17.3

Group	Vaccine		The stimulation index of enhance immunity after 1 week
						Antigen	Adjuvant prescription	AMT	STDEV
1	CSFV-E2	No adjuvant	176	95
					2	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	11,719	13,401
3	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [80/320/80]	7,112	3,247
					4	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [40/160/40]	5,557	3,933
5	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/L1695[40/160/40]	4,092	2,718
					6	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/(sulfuric ester) 4-(lauroyl) 4-sucrose [40/160/40]	3,072	3,832
7	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/(sulfuric ester) 4-(lauroyl) 4-sucrose [80/320/80]	8,351	3,885
					8	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/Markol/ PS [40/160/40]	7,078	1,428
9	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/silicone oil/PS [40/160/40]	25,760	25,126
					10	CSFV-E2	(sulfuric ester) 1-(lauroyl) 7-sucrose/perfluoro-octyl bromide/PS [40/160/40]	19,209	35,430

NT=does not detect

Embodiment #18

Press method described in the embodiment #1, by making 23.9g sucrose and 94g decanoyl chloride and 11.1g SO ₃The contact of-pyridine, synthetic (sulfuric ester) 1-(caprinoyl) 7-sucrose.This sucrose ester carries out extracting by method described in the foregoing description #2 with normal hexane.

Press method described in the embodiment #1, by making 24g sucrose and 54.4g decanoyl chloride and 45g SO ₃The contact of-pyridine, synthetic (sulfuric ester) 4-(caprinoyl) 4-sucrose.By the TLC method described in the embodiment #1 product that obtains is analyzed.The results are shown in figure #18.

With squalane or Squalene as oil, PS, L1695 (Mitsubishi-Kagaku) or (sulfuric ester) 4-(caprinoyl) 4-sucrose prepare several adjuvant prescriptions of these sucrose ester as emulsifying agent and/or stabilizing agent and PBS-thimerosal by the amount shown in the table #18.1.These preparations carry out emulsifying by method described in the foregoing description #1.

Table #18.1

Emulsion	Form
						Sucrose ester	Oil	Emulsifying agent/stabilizing agent	Water
(sulfuric ester) 1-(caprinoyl) 7-sucrose/squalane/PS [40/160/40]	10g (sulfuric ester) 1-(caprinoyl) 7-sucrose	The 40g squalane	The 10g PS	190g PBS-thimerosal
					(sulfuric ester) 1-(caprinoyl) 7-sucrose/squalane/L1695[40/160/40]	10g (sulfuric ester) 1-(caprinoyl) 7-sucrose	The 40g squalane	10g L1695	190g PBS-thimerosal
(sulfuric ester) 1-(caprinoyl) 7-sucrose/squalane/(sulfuric ester) 4-(caprinoyl) 4-sucrose [40/160/40]	10g (sulfuric ester) 1-(caprinoyl) 7-sucrose	The 40g squalane	10g (sulfuric ester) 4-(caprinoyl) 4-sucrose	190g PBS-thimerosal
					(sulfuric ester) 1-(caprinoyl) 7-sucrose/Squalene/PS [40/160/40]	10g (sulfuric ester) 1-(caprinoyl) 7-sucrose	The 40g Squalene	The 10g PS	190g PBS-thimerosal
(sulfuric ester) 1-(caprinoyl) 7-sucrose/Squalene/L1695[40/160/40]	10g (sulfuric ester) 1-(caprinoyl) 7-sucrose	The 40g Squalene	10gL1695	190g PBS-thimerosal
					(sulfuric ester) 1-(caprinoyl) 7-sucrose/Squalene/(sulfuric ester) 4-(caprinoyl) 4-sucrose [40/160/40]	10g (sulfuric ester) 1-(caprinoyl) 7-sucrose	The 40g Squalene	10g (sulfuric ester) 4-(caprinoyl) 4-sucrose	190g PBS-thimerosal

The explanation of table #18.1: squalane (Merck), Squalene (Merck), PS (Merck), Spheron MD 30/70 20 (Baker), L1695 (Mitsubishi-Kagaku food company, Tokyo, Japan), WFI is water for injection (ID-Lelystad, Lelystad, Holland).

Measure the effect of the anti-CSFV-E2 immunne response of these (several) preparations on one's body pig by method described in the foregoing description #1.1 group has 5 pigs, and 2 groups and 3 groups respectively have 4 pigs.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that the ELISA described in the foregoing description #3 measures anti-CSFV in the serum.The results are shown in table #18.2.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #18.3.

Table #18.2

Group	Vaccine		In the enhance immunity 1 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	6.4	2.0	86
						2	CSFV-E2	(sulfuric ester) 1-(caprinoyl) 7-sucrose/Squalene/PS [40/160/40]	13.6	1.0	12,024
3	CSFV-E2	(sulfuric ester) 1-(caprinoyl) 7-sucrose/Squalene/L1695[40/160/40]	14.6	0.5	25,063

Table #18.3

Group	Vaccine		The stimulation index of enhance immunity after 1 week
						Antigen	Adjuvant prescription	AMT	STDEV
1	CSFV-E2	No adjuvant	176	95
					2	CSFV-E2	(sulfuric ester) 1-(caprinoyl) 7-sucrose/Squalene/PS [40/160/40]	2,609	866
3	CSFV-E2	(sulfuric ester) 1-(caprinoyl) 7-sucrose/Squalene/L1695[40/160/40]	3,353	2,092

NT=does not detect

Embodiment #19

With L195 (Mitsubishi), Squalene (Merck), L1695 (Mitsubishi) and PBS-thimerosal or WFI, prepare preparation by the amount shown in the table #19.1.These preparations carry out emulsifying by method described in the foregoing description #1.

Table #19.1

Emulsion	Form
						Sucrose ester	Oil	Emulsifying agent/stabilizing agent	Water
L195/ Squalene/L1695[40/160/40]	10g L1695	The 40g Squalene	10g L1695	190g PBS-thimerosal
					L195/ Squalene/L1695[80/320/80]	20g L1695	The 80g Squalene	20g L1695	130g PBS-thimerosal
L195/ Squalene/L1695 [120/480/120]	30g L1695	The 120g Squalene	30g L1695	70g PBS-thimerosal
					L195/ Squalene/L1695 [160/640/160]	40g L1695	The 160g Squalene	40g L1695	10g WFI

Squalene (Merck), L195 and L1695 (Mitsubishi-Kagaku), PBS-thimerosal and WFI (ID-Lelystad, Lelystad, Holland).

Measure the effect of these two anti-CSFV-E2 immunne response of preparation on one's body pig by method described in the foregoing description #1.1 group has 5 pigs, and 2 groups and 3 groups respectively have 4 pigs.Vaccine is mixed by a volume adjuvant prescription and a volume antigen preparation simply.Press the antibody titer that the ELISA described in the foregoing description #3 measures anti-CSFV in the serum.The results are shown in table #19.2.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #19.3.

Table #19.2

Group	Vaccine		In the enhance immunity 1 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	6.4	2.0	86
						2	CSFV-E2	L195/ Squalene/L1695 [40/160/40]	13.0	1.5	8,212
3	CSFV-E2	L195/ Squalene/L1695 [80/320/80]	13.0	1.5	7,887

Table #19.3

Group	Vaccine		The stimulation index of enhance immunity after 1 week
						Antigen	Adjuvant prescription	AMT	STDEV
1	CSFV-E2	No adjuvant	176	95
					2	CSFV-E2	L195/ Squalene/L1695[40/160/40]	2,949	2,418
3	CSFV-E2	L195/ Squalene/L1695[80/320/80]	7,338	4,515

NT=does not detect

Embodiment #20

Synthetic (caprinoyl) 7-sucrose ester of the method described in the embodiment #1 of pressing.23.9g fine-powdered sucrose (Merck) is contacted with 94g decanoyl chloride (Merck).This sucrose ester carries out extracting by method described in the foregoing description #2 with normal hexane.

By the TLC method described in the embodiment #1 product that obtains is analyzed.

Press method described in the foregoing description #1,, prepare these preparations and carry out emulsifying by the amount shown in the table #20.1 with (caprinoyl) 7-sucrose ester, Squalene, PS and PBS-thimerosal.

Table #20.1

Emulsion	Form
						Sucrose ester	Oil	Emulsifying agent/stabilizing agent	Water
(caprinoyl) 7-sucrose/Squalene/PS [40/160/40]	10g (caprinoyl) 7-sucrose	The 40g Squalene	10g L1695	190g PBS-thimerosal
					(caprinoyl) 7-sucrose/Squalene/PS [120/480/120]	30g (caprinoyl) 7-sucrose	The 120g Squalene	30g L1695	195g PBS-thimerosal

Measure the effect of an anti-CSFV-E2 immunne response in these preparations by method described in the foregoing description #1 on one's body pig.1 group has 5 pigs, and 2 groups have 4 pigs.Press the antibody titer that the ELISA described in the foregoing description #3 measures anti-CSFV in the serum.The results are shown in table #20.2.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #20.3.

Table #20.2

Group	Vaccine		In the enhance immunity 1 week back serum 2-log anti--antibody titer of E2 ELISA
							Antigen	Adjuvant prescription	GMT	STDEV	Antilogarithm
1	CSFV-E2	No adjuvant	6.4	2.0	86
						2	CSFV-E2	(caprinoyl) 7-sucrose/Squalene/PS [40/160/40]	14.1	1.4	17,604

Table #20.3

Group	Vaccine		The stimulation index of enhance immunity after 1 week
						Antigen	Adjuvant prescription	AMT	STDEV
1	CSFV-E2	No adjuvant	176	95
					2	CSFV-E2	(caprinoyl) 7-sucrose/Squalene/PS [40/160/40]	3,023	2,647

NT=does not detect

Embodiment #21

Studied interval between first immunisation and the secondary immunity to the influence of immunne response.With CSFV-E2+ (sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [40/160/40] of embodiment #17, with at interval three weeks (the 0th week and the 3rd week) and two weeks of interval (the 1st all and the 3rd week) to twice of several groups of pig immunity.Press the antibody titer that the ELISA described in the foregoing description #3 measures anti-CSFV in the serum.The results are shown in table #21.1.

Measure replying of cell-mediated anti-CSFV by the lymphocyte proliferation assay described in the foregoing description #2.The results are shown in table #21.2.

Table #21.1

Group	(sulfuric ester) 1-(lauroyl) 7-sucrose/Squalene/PS [40/160/40] of vaccine: CSFV-E2+ embodiment 17		In the enhance immunity 1 week back serum 2-log anti--antibody titer of E2 ELISA
							First immunisation	Secondary immunity	GMT	STDEV	Antilogarithm
1	The 0th week	The 3rd week	12.3	1.1	4,897
						2	The 1st week	The 3rd week	11.2	1.1	2,327

Table #21.2

Group	Vaccine		The stimulation index of enhance immunity after 1 week
						First immunisation	Secondary immunity	AMT	STDEV
1	The 0th week	The 3rd week	3,072	3,832
					2	The 1st week	The 3rd week	3,439	1,803

Embodiment #22

L195//squalane/PS [40/160/40] adjuvant prescription by the preparation of method described in the embodiment #13 mixes with the antigenic solution that contains 3 μ g/ml hoof-and-mouth disease toxic bacterial strain O/Taiwan of similar volume.With the 2ml vaccine to twice of 3 groups of pig immunity.Pressing the described virucidin's detection of vanMaanen and Terpstra (immunization method magazine, 1989,124,111-119 page or leaf) reacts with the anti-O/Taiwan of different time measuring space virucidin.

The results are shown in table #22.1.

Table #22.1

			10 log are anti--antibody titer of O/Taiwan
											Group	First immunisation	Secondary immunity	10 days		17 days		24 days		28 days
			GMT	STDE V	GMT	STDE V	GMT	STDE V	GMT	STDE V
											1	0 day	No reinforcing agent	0.90	0.46	0.55	0.23	0.58	0.22	0.65	0.31
2	0 day	3 days	1.80	0.45	2.05	0.17	1.70	0.38	1.60	0.23
											3	0 day	7 days	1.35	0.26	1.35	0.45	1.20	0.52	1.10	0.23
4	0 day	14 days	0.75	0.15	0.90	0.52	2.05	0.43	2.00	0.62
											5	0 day	21 days	1.45	0.38	1.45	0.38	1.30	0.38	2.80	0.61

Embodiment #23

By method described in the embodiment #1 160g L195,640g squalane, 160g PS and 40g water for injection (L195/ squalane/PS [160/640/160]) adjuvant prescription is carried out emulsifying.This adjuvant prescription with a volume mixes with the antigenic solution that a volume contains 3 μ g/ml hoof-and-mouth disease toxic bacterial strain O/Taiwan.With the 2ml vaccine 5 groups of pig immunity are once also pressed method described in the embodiment #22 with different time measuring space antibody response.The results are shown in table #23.1.

Table #23.1

Inoculation back different time at interval 10 log anti--antibody titer of O/Taiwan
										0 day		7 days		14 days		21 days		28 days
GMT	STDE V	GMT	STDE V	GMT	STDE V	GMT	STDE V	GMT	STDE V
										＜0.3	ND	0.81	0.57	1.83	0.33	1.44	0.31	1.32	0.33

Embodiment #24

With (sulfuric ester) 1-(lauroyl) 7-sucrose component III/ squalane/PS [40/160/40] adjuvant among the embodiment #2 with press (vaccine such as Oonk, 1998,16,1074-1082) described preparation, mix with the conjugated gonadotropin releasing hormone peptide of ovalbumin (G6k-GnRH-connects-dimer-OVA conjugate).With 187 μ g G6k-GnRH-series connection-dimer-OVA conjugate+(sulfuric ester) 1-(lauroyl) 7-sucrose component III/ squalane/PS [40/160/40] to 10 pigs (first group) immunity twice, and with no antigenic (sulfuric ester) 1-(lauroyl) 7-sucrose component III/ squalane/PS [40/160/40] to (second group of 5 pig; Contrast) immunity.With different interval after the 10th all first immunisation and the 17th all secondary immunity, use available from the Amersham medical biotechnology (Buckinghamshire of company, England) iodate GnRH, press (vaccines such as Meloen, 1994,12,741-746) described RIA method is measured the antibody titer of anti-GnRH in the blood serum sample (1/2000 dilution).The results are shown in table #24.1.Press Meloen etc. (vaccine, 1994,12,741-746) described method is measured the testicular weight in the 24th week.The results are shown in table #24.2.

Table #24.1

Group	Vaccine	Inoculation back different time is the antibody titer of anti--GnRH at interval
														10 weeks		14 weeks		17 weeks		20 weeks		24 weeks
		AMT	STD EV	AMT	STD EV	AMT	STD EV	AMT	STD EV	AMT	STD EV
												1	G6k-GnRH-series connection dimer OVA conjugate+(sulfuric ester) 1-(lauroyl) 7-sucrose Fraction III/saualane/PS	0.0	0.0	5.4	5.6	3.4	3.2	67.5	31.5	51.4	29.2
2	(sulfuric ester) 1-(lauroyl) 7-sucrose component III/ squalane/PS	NT		NT		NT		0.5	0.3	NT

NT=does not detect.

Table #24.2

Group	Vaccine	Testicular weight (g)
						24 weeks
		Meansigma methods	STDEV
				1	G6k-GnRH-series connection dimer OVA conjugate+(sulfuric ester) 1-(lauroyl) 7-sucrose component III/ squalane/PS	77.2	79.1
2	(sulfuric ester) 1-(lauroyl) 7-sucrose component III/ squalane/PS	227.6	59.2

Embodiment #25

(sulfuric ester) 1-(lauroyl) 7-sucrose, squalane, PS and the PBS-thimerosal of embodiment #17 are mixed the preparation adjuvant prescription by amount listed among the table #25.1.These mixture carry out emulsifying by the method described in the embodiment #1.

Table #25.1

Emulsion	(sulfuric ester) 1-(lauroyl) 7-sucrose/	Squalane	PS	The PBS-thimerosal
						(g)	(g)	(g)	(g)
(sulfuric ester) 1-(lauroyl) 7-sucrose/PS [40/20]	10	0	5	235
					(sulfuric ester) 1-(lauroyl) 7-sucrose/PS [40/40]	10	0	10	230
(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/20/20]	10	5	5	230
					(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/20/40]	10	5	10	225
(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/40/40]	10	10	10	220
					(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/80/40]	10	20	10	210
(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/160/40]	10	40	10	190
					(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/320/40]	10	80	10	150
(sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS [40/320/80]	10	80	20	140

Embodiment #26

(sulfuric ester) 1-(lauroyl) 7-sucrose, 10g PS (Baker) and 230ml 3w/v% aluminium hydroxide suspension (Alhydrogel ofSuperfos Biosector a/s with 10g embodiment #17, Vedbaeck, Denmark) mix the preparation adjuvant prescription.

Legend

Fig. 1 a: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #1.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (lauroyl) 7-sucrose of embodiment #1;

3 roads: (sulfuric ester) 1-(lauroyl) 7-sucrose of embodiment #1;

4 roads: (lauroyl)-sucrose of embodiment #1;

5 roads: (sulfuric ester) 1-(lauroyl) 5-sucrose of embodiment #1;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 1 b: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #1.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (lauroyl) 3-sucrose of embodiment #1;

3 roads: (sulfuric ester) 1-(lauroyl) 3-sucrose of embodiment #1;

4 roads: (lauroyl) 1-sucrose of embodiment #1;

5 roads: (sulfuric ester) 1-(lauroyl) 1-sucrose of embodiment #1;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 2 a: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #3.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (lauroyl) 7-sucrose of embodiment #3;

3 roads: (sulfuric ester) 1-(lauroyl) 7-sucrose of embodiment #3;

4 roads: (myristoyl) 7-sucrose of embodiment #3;

5 roads: (sulfuric ester) 1-(myristoyl) 7-sucrose of embodiment #3;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 2 b: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #3.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (palmityl) 7-sucrose of embodiment #3;

3 roads: (sulfuric ester) 1-(palmityl) 7-sucrose of embodiment #3;

4 roads: (stearoyl) 7-sucrose of embodiment #3;

5 roads: (sulfuric ester) 1-(stearoyl) 7-sucrose of embodiment #3;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 3 a: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #4.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (lauroyl) 8-sucrose of embodiment #4;

3 roads: (sulfuric ester) 0.5-(lauroyl) 7-sucrose of embodiment #4;

4 roads: (sulfuric ester) 1.0-(lauroyl) 6-sucrose of embodiment #4;

5 roads: (sulfuric ester) 1.5-(lauroyl) 5-sucrose of embodiment #4;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 3 b: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #4.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (sulfuric ester) 2.0-(lauroyl) 4-sucrose of embodiment #4;

3 roads: (sulfuric ester) 2.5-(lauroyl) 3-sucrose of embodiment #4;

4 roads: (sulfuric ester) 3.0-(lauroyl) 2-sucrose of embodiment #4;

5 roads: (sulfuric ester) 3.5-(lauroyl) 1-sucrose of embodiment #4;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 4 a: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #5.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (lauroyl) 8-sucrose of embodiment #5;

3 roads: (sulfuric ester) 1-(lauroyl) 7-sucrose of embodiment #5;

4 roads: (sulfuric ester) 2-(lauroyl) 6-sucrose of embodiment #5;

5 roads: (sulfuric ester) 3-(lauroyl) 5-sucrose of embodiment #5;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 4 b: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #5.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (sulfuric ester) 4-(lauroyl) 4-sucrose of embodiment #5;

3 roads: (sulfuric ester) 5-(lauroyl) 3-sucrose of embodiment #5;

4 roads: (sulfuric ester) 6-(lauroyl) 2-sucrose of embodiment #5;

5 roads: (sulfuric ester) 7-(lauroyl) 1-sucrose of embodiment #5;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 5: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #6.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: (lauroyl) 7-maltose of embodiment #6;

3 roads: (sulfuric ester) 1-(lauroyl) 7-maltose of embodiment #6;

4 roads: (lauroyl) 7-lactose of embodiment #6;

5 roads: (sulfuric ester) 1-(lauroyl) 7-lactose of embodiment #6;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 6: the thin layer chromatography of pressing the derivant of the described method preparation of embodiment #7.

1 road (left side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2;

2 roads: the L195 of embodiment #7;

3 roads: (sulfuric ester) 1-L195 of embodiment #7;

4 roads: (sulfuric ester) 2-L195 of embodiment #7;

5 roads: (sulfuric ester) 2.3-L195 of embodiment #7;

6 roads (right side): (sulfuric ester) 1-(lauroyl) 7-sucrose component III of embodiment #2.

Fig. 7: the chemical constitution of sucrose derivative of the present invention, wherein R1, R2, R3, R4, R ' 1, R ' 2, R ' 3 and R ' the 4th, H or-O-S (=O) (=O)-(wherein R is H, Na, K or NH to OR ₄) or-O-C (=O) (CH ₂) _n-CH3 (wherein n is between 6 to 24).

Fig. 8-12: intramuscular injection contains adjuvant of the present invention, especially (sulfuric ester) 1-(lauroyl) 7-sucrose/squalane/PS emulsion, CSFV-E2 vaccine (embodiment #2 the 5th group) 3 weeks (a) and 6 weeks (b) after, the macro manifestations of local response in 5 animals.Slight fibrosis and edema have been carried out record.

Figure 13-17: after intramuscular injection contains CSFV-E2 vaccine (embodiment #2 the 10th group) 3 weeks (a) and 6 weeks (b) of mineral oil bag water logging water adjuvant, the macro manifestations of local response in 5 animals.Record has been carried out in Granumola, abscess and necrosis.

List of references

1.Hilgers etc., immunity 1986,60,141-146 page or leaf.

2.Hilgers etc., vaccine 1994a, 12,653-660 page or leaf.

3.Hilgers etc., vaccine 1994b, 12,661-665 page or leaf.

4.Hilgers etc., vaccine 1999,17,219-228 page or leaf.

5.Mashihi etc., EP-A-0 295 749.

6.Higers & Platenburg.EP 0549074(EP 92/204034)。

7.Higers, WO 96/20222 or BE 95/00120 (SL-CD is as new chemical entities).

8.Higers, WO 96/20008 (the SL-CD/ squalane is as adjuvant).

9.Nigam etc., cancer research 1978,38,3315-3312 page or leaf.

10.Nigam etc., Da Ying cancer magazine 1982,46,782-793.

11. United States Patent (USP) the 3rd, 432, No. 489.

12.WO 90/02133

13.Bonaventura etc., international immune pharmaceutical journal 1984,6,259-267 page or leaf.

14.Behling etc., Journal of Immunology 1976,117,847-851 page or leaf.

15.Azuma EP 1,572,368(1977)。

16.Nishikawa etc., chemistry medicine bulletin 1981,29,505-513 page or leaf.

17.Bazin etc., carbohydrate compound research 1998,309,189-205 page or leaf.

Claims (23)

1. monosaccharide or two sugar derivativess, said derivant has at least 2 but a no more than N-1 fatty acid ester group, wherein N is the hydroxy number of monosaccharide or disaccharide of this derivant of deriving, described monosaccharide or two sugar derivativess further comprise at least one but a no more than N-2 anionic group, wherein the number of combinations of fatty acid ester and anionic group is no more than N, and wherein said anionic group is selected from sulfate radical, sulfonate radical, phosphate radical, sulfate group and bound phosphate groups.

2. described monosaccharide of claim 1 or two sugar derivativess, wherein said monosaccharide derivatives is derived from having C ₅H ₁₀O ₅The pentose of general formula or have C ₆H ₁₂O ₆The hexose of general formula.

3. described monosaccharide of claim 1 or two sugar derivativess, at least one anionic group of wherein said monosaccharide or two sugar derivativess is for having general formula-SO ₂The sulfuric ester of-OR, or have general formula-PO ₂-(OR) ₂Phosphate ester, wherein R is a univalent cation.

4. described monosaccharide of claim 1 or two sugar derivativess, any one R of wherein said monosaccharide or two sugar derivativess is independently selected from H ⁺, K ⁺, Na ⁺, Li ⁺And NH ₄ ⁺

5. described monosaccharide of claim 1 or two sugar derivativess, each fatty acid ester group of wherein said monosaccharide or two sugar derivativess by general formula-O-C (=O)-(CH ₂) _x-CH ₃, wherein x is 4 at least ,-OC (=O)-(CH ₂) _x-CH=CH-(CH ₂) _y-CH ₃, wherein x+y is 4 at least, or-O-(C=O)-(CH ₂) _x-CH=CH-(CH ₂) _y-CH=CH-(CH ₂) _z-CH ₃, wherein x+y+z represents between 2 to 20.

6. described monosaccharide of claim 5 or two sugar derivativess, each fatty acid ester group of wherein said monosaccharide or two sugar derivativess by general formula-OC (=O)-(CH ₂) _x-CH=CH-(CH ₂) _y-CH ₃Representative, wherein x+y is 4 and no more than 24 at least.

7. described monosaccharide of claim 5 or two sugar derivativess, each fatty acid ester group of wherein said monosaccharide or two sugar derivativess by general formula-OC (=O)-(CH ₂) _x-CH ₃Representative, wherein x is between 6 to 14.

8. described monosaccharide of claim 5 or two sugar derivativess, each fatty acid ester group of wherein said monosaccharide or two sugar derivativess by general formula-OC (=O)-(CH ₂) _x-CH ₃Representative, wherein x is 6 or 8 or 10 or 12.

9. the method for preparing monosaccharide as claimed in claim 1 or two sugar derivativess, wherein this monosaccharide or disaccharide react with acyl chlorides and sulfonating agent in order or simultaneously.

10. the described method of claim 9, wherein this monosaccharide or disaccharide at first react in ambient temperature with acyl chlorides and with sulfonating agent, next with the temperature increase of the mixture of monosaccharide or disaccharide, acyl chlorides and sulfonating agent to 50-70 ℃.

11. claim 9 or 10 described methods, wherein said acyl chlorides are caproyl chloride, caprylyl chloride, decanoyl chloride, lauroyl chloride, myristyl chloride, hexadecanoyl chloride, stearoyl chlorine, oleoyl chloride or its mixture.

12. claim 9 or 10 described methods, wherein this sulfonating agent is selected from gaseous state SO ₃, HClSO ₃, SO ₃-pyridine, SO ₃-2-picoline, SO ₃-2,6-lutidines, SO ₃-dimethyl formamide, SO ₃-trimethylamine, SO ₃-triethylamine, SO ₃-dimethylaniline, SO ₃-N-ethylmorpholine, SO ₃-diethylaniline, SO ₃-dioxs or its mixture.

13. comprise the adjuvant prescription of described monosaccharide of claim 1 or two sugar derivativess, described prescription further contains and the immiscible liquid phase of water (II) and emulsifying agent or stabilizing agent (III).

14. the described adjuvant prescription of claim 13 should be squalane, Squalene, mineral oil, vegetable oil, hexadecane, fluorocarbon or silicone oil with the immiscible liquid phase of water (II) wherein.

15. the described adjuvant prescription of claim 13, wherein this emulsifying agent or stabilizing agent (III) are the hydrophil lipophil balance value greater than 10 nonionic detergent, sugar fatty acid ester or hydrophil lipophil balance value greater than 10 anionic detergent.

16. the described adjuvant prescription of claim 13, wherein this emulsifying agent or stabilizing agent (III) are a kind of monosaccharide or two sugar derivativess, described derivant has at least one but a no more than N-1 fatty acid ester group, and wherein N is the hydroxy number of monosaccharide or disaccharide of this derivant of deriving.

17. the described adjuvant prescription of claim 13, it further contains water (IV).

18. comprise the adjuvant prescription of described monosaccharide of claim 1 or two sugar derivativess, described adjuvant prescription further contains and the immiscible solid phase of water (V).

19. the described adjuvant prescription of claim 18, it further contains water (IV).

20. comprise the adjuvant prescription of described monosaccharide of claim 1 or two sugar derivativess, described adjuvant prescription further contains and the immiscible solid phase of water (V), wherein this solid phase (V) is dissolved salt not.

21. the described adjuvant prescription of claim 20, wherein this not dissolved salt be aluminum or calcium salt.

22. the described adjuvant prescription of claim 20, wherein said aluminum or calcium salt are aluminium hydroxide, aluminum phosphate, calcium phosphate, silicon dioxide or its mixture.

23. the described adjuvant prescription of claim 20, it further contains water (IV).

Images